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The present invention provides protein-based biomarkers and 
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cancer status in a patient. In particular, the biomarkers of this 
invention are useful to classify a subject sample as ovarian 
cancer, ovarian cancer of loW malignant potential, benign 
ovarian disease or other malignant condition. The biomarkers 
can be detected by SELDI mass spectrometry. 
19 Claims, 1 Drawing Sheet 

US 8,465,929 B2 
1 
BIOMARKERS FOR OVARIAN CANCER 
CROSS-REFERENCE TO RELATED CASES 
This case is related to US. Provisional Patent Application 
Nos. 60/693,755, ?led on Jun. 24, 2005, and 60/785,031, ?led 
on Mar. 22, 2006, the teachings of Which are incorporated 
herein by reference. 
FIELD OF THE INVENTION 
This invention relates generally to clinical diagnostics and, 
in particular, to clinical diagnostics for ovarian cancer. 
BACKGROUND OF THE INVENTION 
Ovarian cancer is among the most lethal gynecologic 
malignancies in developed countries. Annually, in the United 
States alone, approximately 23,000 Women are diagnosed 
With the disease and almost 14,000 Women die from it. (Jamal 
et al., CA CancerJ. Clin., 52:23-47 (2002)). Despite progress 
in cancer therapy, ovarian cancer mortality has remained vir 
tually unchanged over the past tWo decades. (Id.) Given the 
steep survival gradient relative to the stage at Which the dis 
ease is diagnosed, early detection remains the most important 
factor in improving long-term survival of ovarian cancer 
patients. 
The poor prognosis of ovarian cancer diagnosed at late 
stages, the cost and risk associated With con?rmatory diag 
nostic procedures, and its relatively loW prevalence in the 
general population together pose extremely stringent require 
ments on the sensitivity and speci?city of a test for it to be 
used for screening for ovarian cancer in the general popula 
tion. 
The identi?cation of tumor markers suitable for the early 
detection and diagnosis of cancer holds great promise to 
improve the clinical outcome of patients. It is especially 
important for patients presenting With vague or no symptoms 
or With tumors that are relatively inaccessible to physical 
examination. Despite considerable effort directed at early 
detection, no cost effective screening tests have been devel 
oped (Paley, Curr Opin. Onc0l., 13(5):399402 (2001)) and 
Women generally present With disseminated disease at diag 
nosis. (OZols et al. Epithelial ovarian cancer. In: Hoskins W J, 
PereZ C A, Young R C, editors. Principles and Practice of 
Gynecologic Oncology. 3rd ed. Philadelphia: Lippincott, 
Williams and Wilkins; pages 981-1057 (2000)). 
The best-characterized tumor marker, CA125, is negative 
in approximately 30-40% of stage I ovarian carcinomas and 
its levels are elevated in a variety of benign diseases. (Meyer 
et al., Br. J. Cancer, 82(9):l535-8 (2000); Buamah, J. Surg. 
Oncol., 75(4):264-5 (2000); Tuxen et al., Cancer Treat. Rev., 
21 (3):21 5-45 (1995)). Its use as a population-based screening 
tool for early detection and diagnosis of ovarian cancer is 
hindered by its loW sensitivity and speci?city (MacDonald et 
al., Eur. J. Obstet. Gynecol. Reprod. Biol., 82(2):l55-7 
(1999); Jacobs et al., Hum. Repr0d., 4(1): 1 -12 (1989); Shih et 
al., Tumor markers in ovarian cancer, Diamandis, Fritsche, 
Lilja, Chan, and SchWartZ, editor; Tumor markers physiol 
ogy, pathobiology, technology and clinical applications, 
Philadelphia: AACC Press; in press). Although pelvic and 
more recently vaginal sonography has been used to screen 
high-risk patients, neither technique has the su?icient sensi 
tivity and speci?city to be applied to the general population 
(MacDonald et al., supra). Recent efforts in using CA125 in 
combination With additional tumor markers (Woolas et al., J. 
National Cancer Inst, 85(21):1748-51 (1993); Woolas et al., 
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Gynecol. Oncol., 59(1): 1 1 1-6 (1995); Zhang et al., Gynecol. 
Oncol., 73(1):56-61 (1999); Zhang et al., Use of Multiple 
Markers to Detect Stage I Epithelial Ovarian Cancers: Neural 
NetWork Analysis Improves Performance, American Society 
of Clinical Oncology (2001); Annual Meeting, Abstract) in a 
longitudinal risk of cancer model (Skates et al., Cancer, 76(10 
Supp):2004-10 (1995)), and in tandem With ultrasound as a 
second line test (Jacobs et al., Br Med. J., 306(6884):1030-34 
(1993); Menon et al., British Journal of Obstetrics and Gyne 
cology, 107(2): 165-69 (2000)) have shoWn promising results 
in improving overall test speci?city, Which is critical for a 
disease such as ovarian cancer that has a relatively loW preva 
lence. 
Due to the dismal prognosis of late stage ovarian cancer, it 
is the general consensus that a physician Will accept a test 
With a minimal positive predictive value of 10%. (Bast et al., 
Cancer Treatment and Research, 107:61-97 (2002)). Extend 
ing this to the general population, a general screening test 
Would require a sensitivity greater than 70% and a speci?city 
of 99.6%. Currently, none of the existing serologic markers, 
such as CA125, CA72-4, or M-CSF, individually delivers 
such a performance (Bast et al., Int. J Biol. Markers, 13: 179 
87 (1998)). 
Thus, there is a critical need for neW serological markers 
that individually or in combination With other markers or 
diagnostic modalities deliver the required sensitivity and 
speci?city for early detection of ovarian cancer (Bast et al., 
Early detection of ovarian cancer: promise and reality, Ova 
rian Cancer: ISIS Medical Media Ltd., Oxford, UK (2001), in 
press). Without an acceptable screening test, early detection 
remains the most critical factor in improving long-term sur 
vival of patients With ovarian cancer. 
Thus, it is desirable to have a reliable and accurate method 
of determining the ovarian cancer status in patients, the 
results of Which can then be used to manage subject treat 
ment. 
SUMMARY OF THE INVENTION 
The present invention ?lls these needs by providing novel 
biomarkers and combinations of biomarkers useful for diag 
nosing ovarian cancer, as Well as methods and kits for using 
the biomarkers to diagnose ovarian cancer. 
More speci?cally, in one aspect, the present invention pro 
vides a method for qualifying ovarian cancer status in a sub 
ject comprising: (a) measuring at least one biomarker in a 
biological sample from the subject, Wherein the at least one 
biomarker is selected from the group consisting of the biom 
arkers of Tables 1, 3 and 4; and (b) correlating the measure 
ment With ovarian cancer status. In one embodiment, the at 
least one biomarker is selected from the group consisting of 
ApoC1, Hemoglobin alpha/beta, ApoAII, ApoCII, Calgranu 
lin C, Calgranulin C (truncated form), Calgranulin A, Calcy 
clin, Transthyretin (doubly charged) and IgG heavy chain. In 
another embodiment, the method involves measuring each of 
ApoC1, Hemoglobin alpha/beta, ApoAII, ApoCII, Calgranu 
lin C, Calgranulin C (truncated form), Calgranulin A, Calcy 
clin, Transthyretin and IgG heavy chain. In another embodi 
ment, the method further comprises measuring some other 
knoWn biomarker for ovarian cancer, such as CA125. 
In another embodiment, the method further comprises 
measuring some other knoWn biomarker for ovarian cancer, 
such as CA125. In a further embodiment, the method further 
comprises measuring and correlating at least one biomarker 
selected from the group consisting of CA125, transferrin, 
haptoglobin, ApoA1, transthyretin, ITIH4 internal fragment, 
beta 2-microglobulin, hepcidin, prostatin, osteopontin, esoi 
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nophil-derived neurotoxin, leptin, prolactin, IGF-II, hemo 
globin and modi?ed forms thereof. In yet another embodi 
ment, the method further comprises CAl25 II, CAl5-3, 
CAl 9-9, CA72-4, CA 195, tumor associated trypsin inhibitor 
(TATI), CEA, placental alkaline phosphatase (PLAP), Sialyl 
TN, galactosyltransferase, macrophage colony stimulating 
factor (M-CSF, CSF- l ), lysophosphatidic acid (LPA), 110 kD 
component of the subject. extracellular domain of the epider 
mal growth factor receptor (pl IOEGFR), tissue kallikreins, 
e.g., kallikrein 6 and kallikrein l0 (NES-l), prostasin, HE4, 
creatine kinase B (CKB), LASA, HER-2/neu, urinary gona 
dotropin peptide, Dianon NB 70/K, Tissue peptide antigen 
(TPA), SMRP, osteopontin, and haptoglobin, leptin, prolac 
tin, insulin-like groWth factorI and insulin-like groWth factor 
II. These additional biomarkers can also be measured and 
correlated using the other methods, kits and softWare of the 
present invention. 
In one embodiment of the above method, the at least one 
biomarker is measured by capturing the biomarker on an 
adsorbent surface of a SELDI probe and detecting the cap 
tured biomarkers by laser desorption-ionization mass spec 
trometry. In another embodiment, the at least one biomarker 
is measured by an immunoassay. This latter method is par 
ticularly useful When the identity of the biomarker is knoWn. 
In one embodiment, the sample is ovarian cyst ?uid. In a 
related embodiment, the adsorbent is a member selected from 
the group consisting of a hydrophobic adsorbent, an anion 
exchange adsorbent, a cation exchange adsorbent and a metal 
chelate adsorbent. In yet another embodiment, the adsorbent 
is a cation exchange adsorbent. 
In another embodiment, the biomarkers of the invention are 
measured by a method other than mass spectrometry or meth 
ods that rely on a measurement of the mass of the biomarker. 
For instance, in certain embodiments, the biomarkers of this 
invention are measured by immunoassay. 
As indicated, the above method is directed to qualifying 
ovarian cancer status. In one embodiment, the correlating is 
performed by a softWare classi?cation algorithm. Generally, 
in the method of the present invention, the ovarian cancer 
status is selected from benign ovarian disease, ovarian cancer 
of loW malignant potential, ovarian cancer (malignant) and 
other malignant conditions. In one embodiment, the ovarian 
cancer status is selected from benign ovarian disease and 
ovarian cancer of loW malignant potential versus ovarian 
cancer (malignant) and other malignant conditions. In 
another embodiment, the ovarian cancer status is selected 
from ovarian cancer of loW malignant potential versus benign 
ovarian disease, ovarian cancer (malignant) and other malig 
nant conditions. In yet another embodiment, the ovarian can 
cer status rules out the possibility of benign ovarian disease. 
In still a further embodiment, the ovarian cancer status rules 
out the possibility of ovarian cancer (malignant) and other 
malignant conditions. 
In another embodiment, the methods described herein of 
detecting biomarkers and correlating the measurements With 
ovarian cancer status further comprise managing subject 
treatment based on the status. In a related embodiment, if the 
measurement correlates With ovarian cancer, then managing 
subject treatment comprises administering a chemotherapeu 
tic agent to the subject. In another embodiment, the methods 
further comprise measuring the at least one biomarker after 
subject management and correlating the measurement With 
disease progression, include determining the rates of disease 
progression. 
The invention also provides a method comprising measur 
ing at least one biomarker in a sample from a subject, Wherein 
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the at least one biomarker is selected from the group consist 
ing of biomarkers of Tables 1, 3 and 4. 
Another embodiment of the invention provides a method 
for determining the course of ovarian cancer comprising (a) 
measuring, at a ?rst time, at least one biomarker in a biologi 
cal sample from the subject, Wherein the at least one biomar 
ker is selected from the group consisting of the biomarkers of 
Tables 1, 3 and 4; and (b) measuring, at a second time, the at 
least one biomarker in a biological sample from the subject; 
and (c) comparing the ?rst measurement and the second mea 
surement; Wherein the comparative measurements determine 
the course of the ovarian cancer. 
In yet another embodiment, the at least one biomarker is 
selected from the group consisting of: ApoCl, Hemoglobin 
alpha/beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C 
(truncated form), Calgranulin A and IgG heavy chain. In a 
further embodiment, the method comprises measuring each 
of the folloWing biomarkers: ApoCl, Hemoglobin alpha/ 
beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C (trun 
cated form), Calgranulin A and IgG heavy chain. In a related 
embodiment, the method comprises additionally measuring 
CA125. 
In still another embodiment, the at least one biomarker is 
selected from the group consisting of: ApoCl, ApoAII, 
ApoCII, Calgranulin A, Calgranulin C, Calcyclin, and Tran 
sthyretin (doubly charged). In another embodiment, the 
method involves measuring each of ApoCl,ApoAII, ApoCII, 
Calgranulin A, Calgranulin C, Calcyclin, and Transthyretin 
(doubly charged). In another embodiment, the method further 
comprises measuring some other knoWn biomarker for ova 
rian cancer, such as CA125. 
In addition to the methods described herein, the invention 
also provides compositions comprising a puri?ed biomol 
ecule selected from the biomarkers of Tables 1, 3 and 4. In 
another embodiment, the invention provides a composition 
comprising a biospeci?c capture reagent, e.g., an antibody, 
that speci?cally binds a biomolecule selected from the biom 
arkers of Tables 1, 3 and 4. In a related embodiment, the 
biospeci?c capture reagent is bound to a solid support. In yet 
another embodiment, the invention provides a composition 
comprising a biospeci?c capture reagent bound to a biomar 
ker of Tables 1, 3 and 4. 
In other embodiments, the invention provides kits. For 
example, in one embodiment, the invention provides a kit 
comprising: (a) a solid support comprising at least one cap 
ture reagent attached thereto, Wherein the capture reagent 
binds at least one biomarker from a ?rst group consisting of 
the biomarkers of Tables 1, 3 and 4; and (b) instructions for 
using the solid support to detect a biomarker of Tables 1, 3 and 
4. In a related embodiment, the kit further comprises instruc 
tions for using the solid support to detect a biomarker selected 
from the group consisting of: ApoCl, Hemoglobin alpha/ 
beta, ApoAII, ApoCII, Calgranulin C, Calgranulin C (trun 
cated form), Calgranulin A and IgG heavy chain. In another 
embodiment, the kit comprises instructions for using the solid 
support to detect each of the biomarkers: ApoCl, Hemoglo 
bin alpha/beta, ApoAII, ApoCII, Calgranulin C, Calgranulin 
C (truncated form), CalgranulinA and I gG heavy chain. In yet 
another embodiment, the kits further comprise instructions 
for using the solid support to detect CA125. 
In still another related embodiment, the kit comprises 
instructions for using the solid support to detect at least one 
biomarker is selected from the group consisting of: ApoCl, 
ApoAII, ApoCII, Calgranulin A, Calgranulin C, Calcyclin, 
and Transthyretin (doubly charged). In another embodiment, 
the kit comprises instructions for using the solid support to 
detect each of ApoCl, ApoAII, ApoCII, Calgranulin A, Cal 
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granulin C, Calcyclin, and Transthyretin (doubly charged). In 
another embodiment, the kit comprises instructions for using 
the solid support to detect some other knoWn biomarker for 
ovarian cancer, such as CAl25. 
In another related embodiment, the solid support of the kits 
comprises a capture reagent is a SELDI probe, Where the 
capture reagent is a hydrophobic adsorbent, an anion 
exchange adsorbent, a cation exchange adsorbent and a metal 
chelate adsorbent. In yet another embodiment, the kits addi 
tionally comprise a container containing at least one of the 
biomarkers of Tables 1, 3 and 4. In yet another embodiment, 
the kits additionally comprise a cation exchange chromatog 
raphy sorbent. 
In another embodiment, the invention provides a kit com 
prising (a) a solid support comprising at least one capture 
reagent attached thereto, Wherein the capture reagents bind at 
least one biomarker selected from the group consisting of the 
biomarkers of Tables 1, 3 and 4; and (b) a container contain 
ing at least one of the biomarkers. In a related embodiment, 
the container contains at least one biomarker selected from 
the group consisting of: ApoCl, Hemoglobin alpha/beta, 
ApoAII, ApoCII, Calgranulin C, Calgranulin C (truncated 
form), Calgranulin A and IgG heavy chain. In yet another 
embodiment, the container contains each of the folloWing 
biomarkers: ApoCl, Hemoglobin alpha/beta, ApoAII, 
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal 
granulinA and I gG heavy chain. In a related embodiment, the 
container further contains CAl25. 
In still another related embodiment, the container contains 
at least one biomarker selected from the group consisting of: 
ApoCl , ApoAII, ApoCII, CalgranulinA, Calgranulin C, Cal 
cyclin, and Transthyretin (doubly charged). In another 
embodiment, the container contains each of ApoCl , ApoAII, 
ApoCII, Calgranulin A, Calgranulin C, Calcyclin, and Tran 
sthyretin (doubly charged). In another embodiment, the con 
tainer further contains CAl25. 
In yet another embodiment, the solid support of the kits 
comprises a capture reagent is a SELDI probe, Where the 
capture reagent is a hydrophobic adsorbent, an anion 
exchange adsorbent, a cation exchange adsorbent and a metal 
chelate adsorbent. In yet another embodiment, the kits addi 
tionally comprise a container containing at least one of the 
biomarkers of Tables 1, 3 and 4. 
The invention additionally provides a software product 
comprising code that accesses data attributed to a sample, the 
data comprising measurement of at least one biomarker in the 
sample, the biomarker selected from the group consisting of 
the biomarkers of Tables 1, 3 and 4; and further comprising 
code that executes a classi?cation algorithm that classi?es the 
ovarian cancer status of the sample as a function of the mea 
surement. In a related embodiment, the softWare product 
classi?es the ovarian cancer status of the sample as a function 
of the measurement of a biomarker selected from the group 
consisting of ApoCl, Hemoglobin alpha/beta, ApoAII, 
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal 
granulin A and IgG heavy chain. In yet another embodiment, 
the classi?cation algorithm classi?es the ovarian cancer sta 
tus of the sample as a function of the measurement of each of 
the biomarkers: ApoCl, Hemoglobin alpha/beta, ApoAII, 
ApoCII, Calgranulin C, Calgranulin C (truncated form), Cal 
granulin A and IgG heavy chain. In yet another embodiment, 
the classi?cation algorithm classi?es the ovarian cancer sta 
tus of the sample further as a function of the measurement of 
CA1 25. 
In a related embodiment, the softWare product classi?es the 
ovarian cancer status of the sample as a function of the mea 
surement of a biomarker selected from the group consisting 
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of: ApoCl, ApoAII, ApoCII, Calgranulin A, Calgranulin C, 
Calcyclin, and Transthyretin (doubly charged). In another 
embodiment, the classi?cation algorithm classi?es the ova 
rian cancer status of the sample as a function of the measure 
ment of each of the biomarkers: ApoCl, ApoAII, ApoCII, 
Calgranulin A, Calgranulin C, Calcyclin, and Transthyretin 
(doubly charged). In another embodiment, the classi?cation 
algorithm classi?es the ovarian cancer status of the sample 
further as a function of the measurement of CAl25. 
The present invention additionally provides a method 
Which comprises detecting a biomarker of Tables 1, 3 and 4 by 
mass spectrometry or immunoassay. 
In another embodiment, the invention provides a method 
comprising communicating to a subject a diagnosis relating 
to ovarian cancer status determined from the correlation of 
biomarkers in a sample from the subject, Wherein the biom 
arkers are selected from the group consisting of the biomar 
kers of Tables 1, 3 and 4. In a related embodiment, the diag 
nosis is communicated to the subject via a computer 
generated medium. 
In another embodiment, the present invention provides a 
method for identifying a compound that interacts With a 
biomarker of Tables 1, 3 and 4, Wherein the method comprises 
(a) contacting a biomarker of Tables 1, 3 and 4 With a test 
compound; and (b) determining Whether the test compound 
interacts With the biomarker of Tables 1, 3 and 4. 
In another embodiment, the invention provides a method 
for modulating the concentration of Calgranulin C in a cell, 
Wherein the method comprises contacting said cell With an 
inhibitor, Wherein said inhibitor prevents cleavage of Cal 
granulin C. 
The invention additionally provides a method of treating a 
condition in a subject, Wherein saidmethod comprises admin 
istering to a subject a therapeutically effective amount of an 
inhibitor of Calgranulin C, Wherein the inhibitor prevents 
cleavage of Calgranulin C. In a related embodiment, said 
condition is ovarian cancer. 
Other features, objects and advantages of the present 
invention and its preferred embodiments Will become appar 
ent from the detailed description, examples and claims that 
folloW. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Representative spectra (A) and corresponding gel 
vieWs (B) of cyst ?uids from individual patients With benign 
(a, a'), malignant epithelial ovarian cancer (b, b'), and loW 
malignant potential tumors. Fractionated by anion exchange 
With descending pH (pH 9.0, 7.0, 5.0, 4.0, 3.0), then organic 
solvent, adsorbed to CMl0 ProteinChip arrays, and read at 
loW laser intensity. pH 9.0 elution fractions are shoWn for 
each patient. Representative scatter and box plots (C) shoW 
variability in “peak intensity” for m/Z 10,840 (calgranulinA). 
The horizontal line in each scatter plot is the mean “peak 
intensity”. Peak m/Z 10,840 has signi?cantly greater “peak 
intensity” in patients With malignant epithelial ovarian can 
cer. 
DETAILED DESCRIPTION OF THE INVENTION 
AND PREFERRED EMBODIMENTS 
I. Introduction 
A biomarker is an organic biomolecule Which is differen 
tially present in a sample taken from a subject of one pheno 
typic status (e.g., having a disease) as compared With another 
phenotypic status (e.g., not having the disease). A biomarker 
US 8,465,929 B2 
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is differentially present between different phenotypic statuses 
if the mean or median expression level of the biomarker in the 
different groups is calculated to be statistically signi?cant: 
Common tests for statistical signi?cance include, among oth 
ers, t-test, ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whit 
ney and odds ratio. Biomarkers, alone or in combination, 
provide measures of relative risk that a subject belongs to one 
phenotypic status or another. Therefore, they are useful as 
markers for disease (diagnostics), therapeutic effectiveness 
8 
biomolecules are discriminated. In one aspect, this invention 
provides these biomarkers in isolated form. 
The biomarkers were discovered using SELDI technology 
employing ProteinChip arrays from Ciphergen Biosystems, 
Inc. (Fremont, Calif.) (“Ciphergen”). Ovarian cyst ?uid was 
collected from subjects diagnosed with ovarian cancer (inva 
sive epithelial ovarian cancer), ovarian cancer of low malig 
nant potential (borderline disease), other malignant condi 
tions and benign ovarian disease. A portion of the samples 
of a drug (theranostics) and drug toxicity, 10 were left unfactionated and the other portion of samples were 
fractionated by anion exchange chromatography. Unfraction 
II. Biomarkers for Ovarian Cancer ated and fractionated samples were applied to SELDI bio 
chips and spectra of polypeptides in the samples were gener 
This invention provides polypeptide-based biomarkers that ated by time-of-?ight mass spectrometry on a Ciphergen 
are differentially present in subjects having ovarian cancer, in 15 PBSII mass spectrometer. The spectra thus obtained were 
particular, ovarian cancer (malignant, such as invasive epi- analyZed by Ciphergen ExpressTM Data Manager Software 
thelial ovarian cancer), ovarian cancer of low malignant with Biomarker WiZard and Biomarker Pattern Software 
potential ((LMP), borderline disease), benign ovarian disease from Ciphergen Biosystems, Inc. The mass spectra for each 
and other malignant conditions (such as malignancies other group were subjected to scatter plot analysis. A Mann-Whit 
than invasive epithelial ovarian cancer, including metastatic 20 ney test analysis was employed to compare ovarian cancer 
cancer (e.g., gastric cancer metastasiZed to the ovary), and control groups for each protein cluster in the scatter plot, 
mesothelioma, a stromal ovarian cancer, etc.)). The biomar- and proteins were selected that differed signi?cantly 
kers are characterized by mass-to-charge ratio as determined (p<0.000l ) between the two groups. This method is described 
by mass spectrometry, by the shape of their spectral peak in in more detail in the Example Section. 
time-of-?ight mass spectrometry and by their binding char- 25 The biomarkers thus discovered are presented in Table l. 
acteristics to adsorbent surfaces. These characteristics pro- The “ProteinChip assay” column refers to chromatographic 
vide one method to determine whether a particular detected fraction, if applicable) in which the biomarker is found, the 
biomolecule is a biomarker of this invention. These charac- type of biochip to which the biomarker binds and whether the 
teristics represent inherent characteristics of the biomol- biomarker is up- or down-regulated in ovarian cancer, as per 
ecules and not process limitations in the manner in which the the Example Section. 
TABLE 1 
Up or down 
regulated in 
Marker ID, m/Z P-Value ovarian cancer ProteinChip ® assay 
M6420/6640 <0.001 Up in Unfractionated, H50, Q10 
ApoCI Malignancy2 Fraction 1, CM10 
M7570/7930 <0.001 Up in Unfractionated, Q10 
Hemoglobin Malignancy 
Alpha/Betal 
M8690/8810 <0.001 Down in LMI’3 Unfractionated, H50, Q10 
ApoAII 
M8920 <0.001 Down in LMP Unfractionated, H50 
ApoCII 
M10210 <0.001 r/o Benign4 Unfractionated, H50, Q10 
Calcyclin 
M10430 <0.001 r/o Benign Unfractionated, H50, Q10 
Calgranulin C 
M54000 <0.001 r/o Malignancy4 Unfractionated, IMAC, H50 
IgG heavy chain Fraction 4, IMAC30 
M10840 <0.001 r/o Benign Fraction 1, CM10, IMAC30 
Calgranulin A 
M32600 <0.001 Down in Fraction 1, CM10 
Malignancy6 
M51000 <0.001 Down in Fraction 3, CM10, IMAC30 
Malignancy 
M6880 <0.001 Up in Fraction 4, CM10 
Transthyretin Malignancy 
(doubly charged) 
M8660 <0.001 Down in LMP Fraction 4, CM10 
ApoII 
M75000 <0.001 Up in Fraction 4, CM10 
Malignancy 
M83820 <0.001 Up in Fraction 4, CM10 
Malignancy 
M94500 <0.001 Up in Fraction 4, CM10 
Malignancy 
M146000 <0.001 Up in Fraction 4, CM10 
Malignancy 
M4249 <0.001 Up in Fraction 5, CM10 
Malignancy 
M4562 <0.001 Up in Fraction 5, CM10 
Mali gnancy 
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TABLE l-continued 
Up or down 
regulated in 
Marker ID, m/z P-Value ovarian cancer ProteinChip ® assay 
M4630 <0.001 Up in Fractions 4, 5, IMAC30, CM10 
Malignancy 
M6936 <0.001 Up in Fraction 5, CM10 
Malignancy 
M63000 <0.001 Down in Fraction 6, CM10 
Malignancy 
1It is noted that the hemoglobin alpha and hemoglobin beta are doubly charged in the SELDI detection assay 
set forth in the Example Section 
2“Up in Malignancy” means that the biomarker is up-regulated in ovarian cancer and other malignant 
conditions (such as malignancies other than invasive epithelial ovarian cancer, including metastatic cancer 
(e.g., gastric cancer frequently metastasizes to the ovary), mesothelioma, a stromal ovarian cancer, etc.) versus 
benign ovarian disease and ovarian cancer oflow malignant potential (LMP) (borderline disease). 
“Down in LMIP” means that the biomarker is down-regulated in ovarian cancer oflow malignant potential 
versus the other three groups (i.e., benign ovarian disease, ovarian cancer (malignant) and other malignant 
conditions). 
4“r/o benign” means that the presence ofthe biomarker rules out the possibility ofbenign disease, but it is not 
adequate, alone, to made a diagnosis among the other three groups (ovarian cancer LMIP, ovarian cancer 
(malignant) and other malignant conditions). 
“r/o Malignant” means that the presence ofthe biomarker rules out the possibility ofmalignant disease, but 
is not adequate on its own to make a diagnosis of benign ovarian disease. 
‘Down in Malignancy” means that the biomarker is up-regulated in ovarian cancer and other malignant 
conditions versus benign ovarian disease and ovarian cancer of low malignant potential (LMP) (borderline 
10 
disease). 
The biomarkers of this invention are characterized by their 
mass-to-charge ratio as determined by mass spectrometry. 
The mass-to-charge ratio of each biomarker is provided in 
Table 1, above, Tables 2 and 3, below, after the “M.” Thus, for 
example, M6420 has a measured mass-to-charge ratio of 
6420. The mass-to-charge ratios were determined from mass 
spectra generated on a Ciphergen Biosystems, Inc. PBS II 
mass spectrometer. This instrument has a mass accuracy of 
about +/—0.15 percent. Additionally, the instrument has a 
mass resolution of about 400 to 1000 m/dm, where m is mass 
and dm is the mass spectral peak width at 0.5 peak height. The 
mass-to-charge ratio of the biomarkers was determined using 
Biomarker WizardTM software (Ciphergen Biosystems, Inc.). 
Biomarker Wizard assigns a mass-to-charge ratio to a biom 
arker by clustering the mass-to-charge ratios of the same 
peaks from all the spectra analyzed, as determined by the 
PBSII, taking the maximum and minimum mass-to-charge 
ratio in the cluster, and dividing by two. Accordingly, the 
masses provided re?ect these speci?cations. 
The biomarkers of this invention are further characterized 
by the shape of their spectral peak in time-of-?ight mass 
spectrometry. 
The biomarkers of this invention are further characterized 
by their binding properties on chromatographic surfaces. 
Examples of chromatographic surfaces that the biomarkers of 
this invention bind include, but are not limited to, a hydro 
phobic adsorbent (such as the Ciphergen® H50 Protein 
Chip® array), an anion exchange adsorbent (such as the 
Ciphergen® Q10 ProteinChip® array), a cation exchange 
adsorbent (such as the Ciphergen® CM10 ProteinChip® 
array) and a metal chelate adsorbent (such as the Ciphergen® 
IMAC-30 ProteinChip® array). A number of the biomarkers 
bind to a hydrophobic adsorbent (such as the Ciphergen® 
H50 ProteinChip® array) using a binding and washing buffer 
of 10% acetonitrile. Some of the biomarkers bind to an anion 
exchange adsorbent (such as the Ciphergen® Q10 Protein 
Chip® array) using a binding and washing buffer of 50 mM 
Tris buffer at pH 8.0. A number of the biomarkers bind to a 
metal chelate adsorbent (such as the Ciphergen® IMAC-30 
ProteinChip® array coupled with copper) using, for example, 
a binding and washing buffer of 50 mM Tris pH 8.0/ 500 mM 
NaCl. Most of the biomarkers bind to cation exchange adsor 
bents (e.g., the Ciphergen CM10 ProteinChip® array) after 
washing with 100 mM sodium acetate at pH 4. 
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The identity of certain of the biomarkers of this invention 
has been determined and is indicated in Table 1. The method 
by which this determination was made is described in the 
Example Section. For biomarkers whose identify has been 
determined, the presence of the biomarker can be determined 
by other methods known in the art (e.g., by immunoassay). 
Because the biomarkers of this invention are characterized 
by mass-to-charge ratio, binding properties and spectral 
shape, they can be detected by mass spectrometry without 
knowing their speci?c identity. However, if desired, biomar 
kers whose identity is not determined can be identi?ed by, for 
example, determining the amino acid sequence of the 
polypeptides. For example, a biomarker can be peptide 
mapped with a number of enzymes, such as trypsin or V8 
protease, and the molecular weights of the digestion frag 
ments can be used to search databases for sequences that 
match the molecular weights of the digestion fragments gen 
erated by the various enzymes. Alternatively, protein biom 
arkers can be sequenced using tandem MS technology. In this 
method, the protein is isolated by, for example, gel electro 
phoresis. A band containing the biomarker is cut out and the 
protein is subject to protease digestion. Individual protein 
fragments are separated by a ?rst mass spectrometer. The 
fragment is then subjected to collision-induced cooling, 
which fragments the peptide and produces a polypeptide lad 
der. A polypeptide ladder is then analyzed by the second mass 
spectrometer of the tandem MS. The difference in masses of 
the members of the polypeptide ladder identi?es the amino 
acids in the sequence. An entire protein can be sequenced this 
way, or a sequence fragment can be subjected to database 
mining to ?nd identity candidates. 
The preferred biological source for detection of the biom 
arkers is ovarian cyst ?uid. However, in other embodiments, 
the biomarkers are detected in otherbodily ?uids, e.g., serum, 
blood or urine. 
The biomarkers of this invention are biomolecules. 
Accordingly, this invention provides these biomolecules in 
isolated form. The biomarkers can be isolated from biological 
?uids, such as urine or serum. They can be isolated by any 
method known in the art, based on both their mass and their 
binding characteristics. For example, a sample comprising 
the biomolecules can be subject to chromatographic fraction 
ation, as described herein, and subject to further separation 
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by, e.g., acrylamide gel electrophoresis. Knowledge of the 
identity of the biomarker also alloWs their isolation by immu 
noa?inity chromatography. 
III. Biomarkers and Different Forms of a Protein 
Proteins frequently exist in a sample in a plurality of dif 
ferent forms characterized by a detectably different mass. 
These forms can result from either or both of pre- and post 
translational modi?cation. Pre-translational modi?ed forms 
include allelic variants, slice variants and RNA editing forms. 
Post-translationally modi?ed forms include forms resulting 
from proteolytic cleavage (e.g., fragments of a parent pro 
tein), glycosylation, phosphorylation, lipidation, oxidation, 
methylation, cystinylation, sulphonation and acetylation. 
When detecting or measuring a protein in a sample, the ability 
to differentiate betWeen different forms of a protein depends 
upon the nature of the difference and the method used to 
detect or measure. For example, an immunoassay using a 
monoclonal antibody Will detect all forms of a protein con 
taining the eptiope and Will not distinguish betWeen them. 
HoWever, a sandWich immunoassay that uses tWo antibodies 
directed against different epitopes on a protein Will detect all 
forms of the protein that contain both epitopes and Will not 
detect those forms that contain only one of the epitopes. In 
diagnostic assays, the inability to distinguish different forms 
of a protein has little impact When the forms detected by the 
particular method used are equally good biomarkers as any 
particular form. HoWever, When a particular form (or a subset 
of particular forms) of a protein is a better biomarker than the 
collection of different forms detected together by a particular 
method, the poWer of the assay may suffer. In this case, it is 
useful to employ an assay method that distinguishes betWeen 
forms of a protein and that speci?cally detects and measures 
a desired form or forms of the protein. Distinguishing differ 
ent forms of an analyte or speci?cally detecting a particular 
form of an analyte is referred to as “resolving” the analyte. 
Mass spectrometry is a particularly poWerful methodology 
to resolve different forms of a protein because the different 
forms typically have different masses that can be resolved by 
mass spectrometry. Accordingly, if one form of a protein is a 
superior biomarker for a disease than another form of the 
biomarker, mass spectrometry may be able to speci?cally 
detect and measure the useful form Where traditional immu 
noassay fails to distinguish the forms and fails to speci?cally 
detect to useful biomarker. 
One useful methodology combines mass spectrometry 
With immunoassay. First, a biospeci?c capture reagent (e.g., 
an antibody, aptamer or A?ibody that recogniZes the biomar 
ker and other forms of it) is used to capture the biomarker of 
interest. Preferably, the biospeci?c capture reagent is bound 
to a solid phase, such as a bead, a plate, a membrane or an 
array. After unbound materials are Washed aWay, the captured 
analytes are detected and/ or measured by mass spectrometry. 
(This method also Will also result in the capture of protein 
interactors that are bound to the proteins or that are otherWise 
recogniZed by antibodies and that, themselves, can be biom 
arkers.) Various forms of mass spectrometry are useful for 
detecting the protein forms, including laser desorption 
approaches, such as traditional MALDI or SELDI, and elec 
trospray ioniZation. 
Thus, When reference is made herein to detecting a particu 
lar protein or to measuring the amount of a particular protein, 
it means detecting and measuring the protein With or Without 
resolving various forms of protein. For example, the step of 
“measuring Calgranulin C” includes measuring any and/or all 
forms of Calgranulin C by means that do not differentiate 
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betWeen various forms of the protein in a sample (e.g., certain 
immunoassays) as Well as by means that differentiate some 
forms from other forms or that measure a speci?c form of the 
protein (e.g., mass spectrometry). In contrast, When it is 
desired to measure a particular form or forms of a protein 
(e.g., a particular form of Calgranulin C including forms 
modi?ed by truncation, phosphorylation, glycosylation, etc.), 
the particular form (or forms) is speci?ed. For example, 
“measuring M10430” means measuring a polypeptide having 
an apparent molecular Weight of 10430 Da that, therefore, 
distinguishes M10430 from other forms of Calgranulin C. 
IV. Detection of Biomarkers for Ovarian Cancer 
The biomarkers of this invention can be detected by any 
suitable method. Detection paradigms that can be employed 
to this end include optical methods, electrochemical methods 
(voltametry and amperometry techniques), atomic force 
microscopy, and radio frequency methods, e.g., multipolar 
resonance spectroscopy. Illustrative of optical methods, in 
addition to microscopy, both confocal and non-confocal, are 
detection of ?uorescence, luminescence, chemilumines 
cence, absorbance, re?ectance, transmittance, and birefrin 
gence or refractive index (e.g., surface plasmon resonance, 
ellipsometry, a resonant mirror method, a grating coupler 
Waveguide method or interferometry). 
In one embodiment, a sample is analyZed by means of a 
biochip. Biochips generally comprise solid substrates and 
have a generally planar surface, to Which a capture reagent 
(also called an adsorbent or af?nity reagent) is attached. Fre 
quently, the surface of a biochip comprises a plurality of 
addressable locations, each of Which has the capture reagent 
bound there. 
Protein biochips are biochips adapted for the capture of 
polypeptides. Many protein biochips are described in the art. 
These include, for example, protein biochips produced by 
Ciphergen Biosystems, Inc. (Fremont, Calif.), Zyomyx (Hay 
Ward, Calif.), Invitrogen (Carlsbad, Calif.), Biacore (Upp 
sala, SWeden) and Procognia (Berkshire, UK). Examples of 
such proteinbiochips are described in the folloWing patents or 
published patent applications: U.S. Pat. No. 6,225,047 
(Hutchens et al.); U.S. Pat. No. 6,537,749 (Kuimelis et al.); 
U.S. Pat. No. 6,329,209 (Wagner et al.); PCT International 
Publication No. WO 00/56934 (Englert et al.); PCT Intema 
tional Publication No. WO 03/048768 (Boutell et al.) and 
Us. Pat. No. 5,242,828 (Bergstrom et al.). 
Detection by Mass Spectrometry 
In a preferred embodiment, the biomarkers of this inven 
tion are detected by mass spectrometry, a method that 
employs a mass spectrometer to detect gas phase ions. 
Examples of mass spectrometers are time-of-?ight, magnetic 
sector, quadrupole ?lter, ion trap, ion cyclotron resonance, 
electrostatic sector analyZer and hybrids of these. 
In a further preferred method, the mass spectrometer is a 
laser desorption/ionization mass spectrometer. In laser des 
orption/ioniZation mass spectrometry, the analytes are placed 
on the surface of a mass spectrometry probe, a device adapted 
to engage a probe interface of the mass spectrometer and to 
present an analyte to ioniZing energy for ioniZation and intro 
duction into a mass spectrometer. A laser desorption mass 
spectrometer employs laser energy, typically from an ultra 
violet laser, but also from an infrared laser, to desorb analytes 
from a surface, to volatiliZe and ioniZe them and make them 
available to the ion optics of the mass spectrometer. The 
analysis of proteins by LDI can take the form of MALDI or of 
SELDI. 
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Laser desorption/ionization in a single TOF instrument 
typically is performed in linear extraction mode. Tandem 
mass spectrometers can employ orthogonal extraction 
modes. 
SELDI 
A preferred mass spectrometric technique for use in the 
invention is “Surface Enhanced Laser Desorption and IoniZa 
tion” or“SELDI,” as described, for example, in US. Pat. Nos. 
5,719,060 and 6,225,047, both to Hutchens et al. This refers 
to a method of desorption/ionization gas phase ion spectrom 
etry (e.g., mass spectrometry) in Which an analyte (here, one 
or more of the biomarkers) is captured on the surface of a 
SELDI mass spectrometry probe. There are several versions 
of SELDI. 
One version of SELDI is called “a?inity capture mass 
spectrometry.” It also is called “Surface-Enhanced Af?nity 
Capture” or “SEAC.” This version involves the use of probes 
that have a material on the probe surface that captures ana 
lytes through a non-covalent a?inity interaction (adsorption) 
betWeen the material and the analyte. The material is vari 
ously called an “adsorbent,” a “capture reagent,” an “a?inity 
reagent” or a “binding moiety.” Such probes can be referred to 
as “a?inity capture probes” and as having an “adsorbent 
surface.” The capture reagent can be any material capable of 
binding an analyte. The capture reagent is attached to the 
probe surface by physisorption or chemisorption. In certain 
embodiments the probes have the capture reagent already 
attached to the surface. In other embodiments, the probes are 
pre-activated and include a reactive moiety that is capable of 
binding the capture reagent, e.g., through a reaction forming 
a covalent or coordinate covalent bond. Epoxide and acyl 
imidiZole are useful reactive moieties to covalently bind 
polypeptide capture reagents such as antibodies or cellular 
receptors. Nitrilotriacetic acid and iminodiacetic acid are use 
ful reactive moieties that function as chelating agents to bind 
metal ions that interact non-covalently With histidine contain 
ing peptides. Adsorbents are generally classi?ed as chro 
matographic adsorbents and biospeci?c adsorbents. 
“Chromatographic adsorbent” refers to an adsorbent mate 
rial typically used in chromatography. Chromatographic 
adsorbents include, for example, ion exchange materials, 
metal chelators (e.g., nitrilotriacetic acid or iminodiacetic 
acid), immobiliZed metal chelates, hydrophobic interaction 
adsorbents, hydrophilic interaction adsorbents, dyes, simple 
biomolecules (e.g., nucleotides, amino acids, simple sugars 
and fatty acids) and mixed mode adsorbents (e.g., hydropho 
bic attraction/ electrostatic repulsion adsorbents). 
“Biospeci?c adsorbent” refers to an adsorbent comprising 
a biomolecule, e.g., a nucleic acid molecule (e.g., an 
aptamer), a polypeptide, a polysaccharide, a lipid, a steroid or 
a conjugate of these (e.g., a glycoprotein, a lipoprotein, a 
glycolipid, a nucleic acid (e.g., DNA)-protein conjugate). In 
certain instances, the biospeci?c adsorbent can be a macro 
molecular structure such as a multiprotein complex, a bio 
logical membrane or a virus. Examples of biospeci?c adsor 
bents are antibodies, receptor proteins and nucleic acids. 
Biospeci?c adsorbents typically have higher speci?city for a 
target analyte than chromatographic adsorbents. Further 
examples of adsorbents foruse in SELDI can be found in US. 
Pat. No. 6,225,047. A “bioselective adsorbent” refers to an 
adsorbent that binds to an analyte With an a?inity of at least 
10-8 M. 
Protein biochips produced by Ciphergen Biosystems, Inc. 
comprise surfaces having chromatographic or biospeci?c 
adsorbents attached thereto at addressable locations. Cipher 
gen’s ProteinChip® arrays include NP20 (hydrophilic); 114 
and H50 (hydrophobic); SAX-2, Q-10 and LSAX-30 (anion 
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exchange); WCX-2, CM-10 and LWCX-30 (cation 
exchange); IMAC-3, IMAC-30 and IMAC-50 (metal che 
late); and PS-10, PS-20 (reactive surface With acyl-imidiZole, 
epoxide) and PG-20 (protein G coupled through acyl-imidi 
Zole). Hydrophobic ProteinChip arrays have isopropyl or 
nonylphenoxy-poly(ethylene glycol)methacrylate function 
alities. Anion exchange ProteinChip arrays have quaternary 
ammonium functionalities. Cation exchange ProteinChip 
arrays have carboxylate functionalities. Immobilized metal 
chelate ProteinChip arrays have nitrilotriacetic acid function 
alities (IMAC-3 and IMAC-30) or O-methacryloyl-N,N-bis 
carboxymethyl tyrosine functionalities (IMAC-50) that 
adsorb transition metal ions, such as copper, nickel, Zinc, and 
gallium, by chelation. Preactivated ProteinChip arrays have 
acyl-imidiZole or epoxide functional groups that can react 
With groups on proteins for covalent binding. 
Such biochips are further described in: US. Pat. No. 6,579, 
719 (Hutchens et al., “Retentate Chromatography,” Jun. 17, 
2003); US. Pat. No. 6,897,072 (Rich et al. “Probes for a Gas 
Phase Ion Spectrometer,” May 24, 2005); US. Pat. No. 6,555, 
813 (Beecher et al., “Sample Holder With Hydrophobic Coat 
ing for Gas Phase Mass Spectrometer,” Apr. 29, 2003); US. 
Patent Publication No. US. 2003 0032043 A1 (Pohl et al. 
“Latex Based Adsorbent Chip,” Jul. 16, 2002); PCT Intema 
tional Publication No. WO 03/040700 (Urn et al., “Hydro 
phobic Surface Chip,” May 15, 2003); US. Patent Publica 
tion No. US 2003/0218130 A1 (Boschetti et al., “Biochips 
With Surfaces Coated With Polysaccharide-Based Hydro 
gels,” Apr. 14, 2003) and US. Pat. No. 7,045,366 (Huang et 
al., “Photocrosslinked Hydrogel Surface Coatings,” May 16, 
2006. 
In general, a probe With an adsorbent surface is contacted 
With the sample for a period of time suf?cient to alloW the 
biomarker or biomarkers that may be present in the sample to 
bind to the adsorbent. After an incubation period, the sub 
strate is Washed to remove unbound material. Any suitable 
Washing solutions can be used; preferably, aqueous solutions 
are employed. The extent to Which molecules remain bound 
can be manipulated by adjusting the stringency of the Wash. 
The elution characteristics of a Wash solution can depend, for 
example, on pH, ionic strength, hydrophobicity, degree of 
chaotropism, detergent strength, and temperature. Unless the 
probe has both SEAC and SEND properties (as described 
herein), an energy absorbing molecule then is applied to the 
substrate With the bound biomarkers. 
In yet another method, one can capture the biomarkers With 
a solid-phase bound immuno-adsorbent that has antibodies 
that bind the biomarkers. After Washing the adsorbent to 
remove unbound material, the biomarkers are eluted from the 
solid phase, applied to a SELDI biochip that binds the biom 
arkers and analyZed by SELDI. 
The biomarkers bound to the substrates are detected in a 
gas phase ion spectrometer such as a time-of-?ight mass 
spectrometer. The biomarkers are ioniZed by an ioniZation 
source such as a laser, the generated ions are collected by an 
ion optic assembly, and then a mass analyZer disperses and 
analyZes the passing ions. The detector then translates infor 
mation of the detected ions into mass-to-charge ratios. Detec 
tion of a biomarker typically Will involve detection of signal 
intensity. Thus, both the quantity and mass of the biomarker 
can be determined. 
SEND 
Another method of laser desorption mass spectrometry is 
called Surface-Enhanced Neat Desorption (“SEND”). SEND 
involves the use of probes comprising energy absorbing mol 
ecules that are chemically bound to the probe surface (“SEND 
probe”). The phrase “energy absorbing molecules” (EAM) 
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denotes molecules that are capable of absorbing energy from 
a laser desorption/ionization source and, thereafter, contrib 
ute to desorption and ionization of analyte molecules in con 
tact therewith. The EAM category includes molecules used in 
MALDI, frequently referred to as “matrix,” and is exempli 
?ed by cinnamic acid derivatives, sinapinic acid (SPA), 
cyano-hydroxy-cinnamic acid (CHCA) and dihydroxyben 
Zoic acid, ferulic acid, and hydroxyaceto-phenone deriva 
tives. In certain embodiments, the energy absorbing molecule 
is incorporated into a linear or cross-linked polymer, e.g., a 
polymethacrylate. For example, the composition can be a 
co-polymer of ot-cyano-4-methacryloyloxycinnamic acid 
and acrylate. In another embodiment, the composition is a 
co-polymer of 0t-cyano-4-methacryloyloxycinnamic acid, 
acrylate and 3-(triethoxy)silyl propyl methacrylate. In 
another embodiment, the composition is a co-polymer of 
ot-cyano-4-methacryloyloxycinnamic acid and octadecyl 
methacrylate (“C18 SEND”). SEND is further described in 
US. Pat. No. 6,124,137 and PCT International Publication 
No. WO 03/64594 (KitagaWa, “Monomers And Polymers 
Having Energy Absorbing Moieties of Use In Desorption/ 
IoniZation Of Analytes,” Aug. 7, 2003). 
SEAC/ SEND is a version of SELDI in Which both a capture 
reagent and an energy absorbing molecule are attached to the 
sample presenting surface. SEAC/ SEND probes therefore 
alloW the capture of analytes through a?inity capture and 
ionization/desorption Without the need to apply external 
matrix. The C18 SEND biochip is a version of SEAC/ SEND, 
comprising a C18 moiety Which functions as a capture 
reagent, and a CHCA moiety Which functions as an energy 
absorbing moiety. 
SEPAR 
Another version of LDI is called Surface-Enhanced Pho 
tolabile Attachment and Release (“SEPAR”). SEPAR 
involves the use of probes having moieties attached to the 
surface that can covalently bind an analyte, and then release 
the analyte through breaking a photolabile bond in the moiety 
after exposure to light, e.g., to laser light (see, US. Pat. No. 
5,719,060). SEPAR and other forms of SELDI are readily 
adapted to detecting a biomarker or biomarker pro?le, pursu 
ant to the present invention. 
MALDI 
MALDI is a traditional method of laser desorption/ioniza 
tionused to analyte biomolecules such as proteins and nucleic 
acids. In one MALDI method, the sample is mixed With 
matrix and deposited directly on a MALDI array. HoWever, 
the complexity of biological samples such as serum and urine 
makes this method less than optimal Without prior fraction 
ation of the sample. Accordingly, in certain embodiments 
With biomarkers are preferably ?rst captured With biospeci?c 
(e. g., an antibody) or chromatographic materials coupled to a 
solid support such as a resin (e.g., in a spin column). Speci?c 
a?inity materials that bind the biomarkers of this invention 
are described above. After puri?cation on the a?inity mate 
rial, the biomarkers are eluted and then detected by MALDI. 
In another mass spectrometry method, the biomarkers are 
?rst captured on a chromatographic resin having chromato 
graphic properties that bind the biomarkers. In the present 
example, this could include a variety of methods. For 
example, one could capture the biomarkers on a cation 
exchange resin, such as CM Ceramic HyperD F resin, Wash 
the resin, elute the biomarkers and detect by MALDI. Alter 
natively, this method could be preceded by fractionating the 
sample on an anion exchange resin before application to the 
cation exchange resin. In another alternative, one could frac 
tionate on an anion exchange resin and detect by MALDI 
directly. In yet another method, one could capture the biom 
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arkers on an immuno-chromatographic resin that comprises 
antibodies that bind the biomarkers, Wash the resin to remove 
unbound material, elute the biomarkers from the resin and 
detect the eluted biomarkers by MALDI or by SELDI. 
Other Forms of IoniZation in Mass Spectrometry 
In another method, the biomarkers are detected by LC-MS 
or LC-LC-MS. This involves resolving the proteins in a 
sample by one or tWo passes through liquid chromatography, 
folloWed by mass spectrometry analysis, typically electro 
spray ioniZation. 
Data Analysis 
Analysis of analytes by time-of-?ight mass spectrometry 
generates a time-of-?ight spectrum. The time-of-?ight spec 
trum ultimately analyZed typically does not represent the 
signal from a single pulse of ioniZing energy against a sample, 
but rather the sum of signals from a number of pulses. This 
reduces noise and increases dynamic range. This time-of 
?ight data is then subject to data processing. In Ciphergen’s 
ProteinChip® softWare, data processing typically includes 
TOF-to-M/Z transformation to generate a mass spectrum, 
baseline subtraction to eliminate instrument offsets and high 
frequency noise ?ltering to reduce high frequency noise. 
Data generated by desorption and detection of biomarkers 
can be analyZed With the use of a programmable digital com 
puter. The computer program analyZes the data to indicate the 
number of biomarkers detected, and optionally the strength of 
the signal and the determined molecular mass for each biom 
arker detected. Data analysis can include steps of determining 
signal strength of a biomarker and removing data deviating 
from a predetermined statistical distribution. For example, 
the observed peaks can be normaliZed, by calculating the 
height of each peak relative to some reference. 
The computer can transform the resulting data into various 
formats for display. The standard spectrum can be displayed, 
but in one useful format only the peak height and mass infor 
mation are retained from the spectrum vieW, yielding a 
cleaner image and enabling biomarkers With nearly identical 
molecular Weights to be more easily seen. In another useful 
format, tWo or more spectra are compared, conveniently high 
lighting unique biomarkers and biomarkers that are up- or 
doWn-regulated betWeen samples. Using any of these for 
mats, one can readily determine Whether a particular biom 
arker is present in a sample. 
Analysis generally involves the identi?cation of peaks in 
the spectrum that represent signal from an analyte. Peak 
selection can be done visually, but softWare is available, as 
part of Ciphergen’ s ProteinChip® softWare package, that can 
automate the detection of peaks. In general, this softWare 
functions by identifying signals having a signal-to-noise ratio 
above a selected threshold and labeling the mass of the peak 
at the centroid of the peak signal. In one useful application, 
many spectra are compared to identify identical peaks present 
in some selected percentage of the mass spectra. One version 
of this softWare clusters all peaks appearing in the various 
spectra Within a de?ned mass range, and assigns a mass (M/Z) 
to all the peaks that are near the mid-point of the mass (M/Z) 
cluster. 
SoftWare used to analyZe the data can include code that 
applies an algorithm to the analysis of the signal to determine 
Whether the signal represents a peak in a signal that corre 
sponds to a biomarker according to the present invention. The 
softWare also can subject the data regarding observed biom 
arker peaks to classi?cation tree or ANN analysis, to deter 
mine Whether a biomarker peak or combination of biomarker 
peaks is present that indicates the status of the particular 
clinical parameter under examination. Analysis of the data 
may be “keyed” to a variety of parameters that are obtained, 
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either directly or indirectly, from the mass spectrometric 
analysis of the sample. These parameters include, but are not 
limited to, the presence or absence of one or more peaks, the 
shape of a peak or group of peaks, the height of one or more 
peaks, the log of the height of one or more peaks, and other 
arithmetic manipulations of peak height data. 
General Protocol for SELDI Detection of Biomarkers for 
Ovarian Cancer 
A preferred protocol for the detection of the biomarkers of 
this invention is as folloWs. In another embodiment, the bio 
logical sample to be tested, e.g., ovarian cyst ?uid, preferably 
is subject to pre-fractionation before SELDI analysis. The 
prefractionation step often simpli?es the sample and 
improves sensitivity. A preferred method of pre-fractionation 
involves contacting the sample With an anion exchange chro 
matographic material, such as Q HyperD (BioSepra, SA). 
The bound materials are then subject to stepWise pH elution 
using buffers at pH 9, pH 7, pH 5 and pH 4. (The fractions in 
Which the biomarkers are eluted also are indicated in Table 1). 
Various fractions containing the biomarker are collected. In 
another embodiment, the biological sample to be tested, e.g., 
ovarian cyst ?uid samples, is not subject to a pre-fractionation 
step, but is used in the chip binding step unfractionated. 
The sample to be tested (either unfractionated or pre-frac 
tionated) is then contacted With an a?inity capture probe. 
Examples of a?inity capture probes of chromatographic sur 
faces that the biomarkers of this invention bind include, but 
are not limited to, a hydrophobic adsorbent (such as the 
Ciphergen® H50 ProteinChip® array), an anion exchange 
adsorbent (such as the Ciphergen® Q10 ProteinChip® 
array), a cation exchange adsorbent (such as the Ciphergen® 
CMl0 ProteinChip® array) and a metal chelate adsorbent 
(such as the Ciphergen® IMAC-30 ProteinChip® array). The 
probe is Washed With a buffer that Will retain the biomarker 
While Washing aWay unbound molecules. A suitable Wash for 
each biomarker is the buffer identi?ed in the Example Sec 
tion. The biomarkers are detected by laser desorption/ioniza 
tion mass spectrometry. 
Alternatively, samples may be diluted, With or Without 
denaturing, in the appropriate array binding buffer and bound 
and Washed under conditions optimiZed for detecting each 
analyte. 
Alternatively, if antibodies that recogniZe the biomarker 
are available, for example in the case of Apolipoprotein Cl 
(ApoCl), hemoglobin alpha, hemoglobin beta, Apolipopro 
teinAII (ApoAII), Apolipoprotein CII (ApoCII), Calgranulin 
C (both full-length and truncated form), Calgranulin A, IgG 
heavy chain, Calcyclin and Transthyretin, these can be 
attached to the surface of a probe, such as a pre-activated 
PSl0 or PS20 ProteinChip array (Ciphergen Biosystems, 
Inc.). These antibodies can capture the biomarkers from a 
sample onto the probe surface. Then the biomarkers can be 
detected by, e. g., laser desorption/ionization mass spectrom 
etry. 
Any robot that performs ?uidics operations can be used in 
these assays, for example, those available from HeWlett Pack 
ard and Hamilton. 
Detection by Immunoassay 
In another embodiment of the invention, the biomarkers of 
the invention are measured by a method other than mass 
spectrometry or methods that rely on a measurement of the 
mass of the biomarker. In another embodiment, the biomar 
kers of this invention are measured by immunoassay. Immu 
noassay requires biospeci?c capture reagents, such as anti 
bodies, to capture the biomarkers. Antibodies can be 
produced by methods Well knoWn in the art, e.g., by immu 
niZing animals With the biomarkers. Biomarkers can be iso 
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lated from samples based on their binding characteristics. 
Alternatively, if the amino acid sequence of a polypeptide 
biomarker is knoWn, the polypeptide can be synthesiZed and 
used to generate antibodies by methods Well knoWn in the art. 
This invention contemplates traditional immunoassays 
including, for example, sandWich immunoassays including 
ELISA or ?uorescence-based immunoassays, as Well as other 
enZyme immunoassays. Nephelometry is an assay done in 
liquid phase, in Which antibodies are in solution. Binding of 
the antigen to the antibody results in changes in absorbance, 
Which is measured. In the SELDI-based immunoassay, a bio 
speci?c capture reagent for the biomarker is attached to the 
surface of an MS probe, such as a pre-activated ProteinChip 
array. The biomarker is then speci?cally captured on the 
biochip through this reagent, and the captured biomarker is 
detected by mass spectrometry. 
V. Determination of Subject Ovarian Cancer Status 
The biomarkers of the invention can be used in diagnostic 
tests to assess ovarian cancer status in a subject, e.g., to 
diagnose ovarian cancer. The phrase “ovarian cancer status” 
includes any distinguishable manifestation of the disease. For 
example, ovarian cancer disease status includes, Without limi 
tation, the presence or absence of disease (e.g., ovarian cancer 
(malignant) versus ovarian cancer of loW malignant potential 
versus benign ovarian disease versus other malignant condi 
tions), the risk of developing disease, the stage of the disease, 
the progress of disease (e.g., progress of disease or remission 
of disease over time) and the effectiveness or response to 
treatment of disease. Based on this status, further procedures 
may be indicated, including additional diagnostic tests or 
therapeutic procedures or regimens. 
The correlation of test results With ovarian cancer status 
applying a classi?cation algorithm of some kind to the results 
to generate the status. The classi?cation algorithm may be as 
simple as determining Whether or not the amount of a given 
biomarker measured is above or beloW a particular cut-off 
number. When multiple biomarkers are used, the classi?ca 
tion algorithm may be a linear regression formula. Altema 
tively, the classi?cation algorithm may be the product of any 
of a number of learning algorithms described herein. 
In the case of complex classi?cation algorithms, it may be 
necessary to perform the algorithm on the data, thereby deter 
mining the classi?cation, using a computer, e.g., a program 
mable digital computer. In either case, one can then record the 
status on tangible medium, for example, in computer-read 
able format such as a memory drive or disk or simply printed 
on paper. The result also could be reported on a computer 
screen. 
Single Markers 
The poWer of a diagnostic test to correctly predict status is 
commonly measured as the sensitivity of the assay, the speci 
?city of the assay or the area under a receiver operated char 
acteristic (“ROC”) curve. Sensitivity is the percentage of true 
positives that are predicted by a test to be positive, While 
speci?city is the percentage of true negatives that are pre 
dicted by a test to be negative. An ROC curve provides the 
sensitivity of a test as a function of l-speci?city. The greater 
the area under the ROC curve, the more poWerful the predic 
tive value of the test. Other useful measures of the utility of a 
test are positive predictive value and negative predictive 
value. Positive predictive value is the percentage of people 
Who test positive that are actually positive. Negative predic 
tive value is the percentage of people Who test negative that 
are actually negative. 
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The biomarkers of this invention show a statistical differ 
ence in different ovarian cancer statuses of at least p§0.05, 
p§l0_2, p§l0_3, p210-4 or p§l0_5. Diagnostic tests that 
use these biomarkers alone or in combination shoW a sensi 
tivity and speci?city of at least 75%, at least 80%, at least 
85%, at least 90%, at least 95%, at least 98% and about 100%. 
Each biomarker listed in Tables 1, 3 and 4 is differentially 
present in ovarian cancer (malignant), in ovarian cancer LMP, 
in benign ovarian disease or in other malignant conditions), 
and, therefore, each is individually useful in aiding in the 
determination of ovarian cancer status. The method involves, 
?rst, measuring the selected biomarker in a subject sample 
using the methods described herein, e.g., capture on a SELDI 
biochip folloWed by detection by mass spectrometry and, 
second, comparing the measurement With a diagnostic 
amount or cut-off that distinguishes a positive ovarian cancer 
status from a negative ovarian cancer status. The diagnostic 
amount represents a measured amount of a biomarker above 
Which or beloW Which a subject is classi?ed as having a 
particular ovarian cancer status. For example, if the biomar 
ker is up-regulated compared to normal during ovarian can 
cer, then a measured amount above the diagnostic cutoff 
provides a diagnosis of ovarian cancer. Alternatively, if the 
biomarker is doWn-regulated during ovarian cancer, then a 
measured amount beloW the diagnostic cutoff provides a 
diagnosis of ovarian cancer. As is Well understood in the art, 
by adjusting the particular diagnostic cut-off used in an assay, 
one can increase sensitivity or speci?city of the diagnostic 
assay depending on the preference of the diagnostician. The 
particular diagnostic cut-off can be determined, for example, 
by measuring the amount of the biomarker in a statistically 
signi?cant number of samples from subjects With the differ 
ent ovarian cancer statuses, as Was done here, and draWing the 
cut-off to suit the diagnostician’s desired levels of speci?city 
and sensitivity. 
Combinations of Markers 
While individual biomarkers are useful diagnostic biom 
arkers, it has been found that a combination of biomarkers can 
provide greater predictive value of a particular status than 
single biomarkers alone. Speci?cally, the detection of a plu 
rality of biomarkers in a sample can increase the sensitivity 
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and/or speci?city of the test. A combination of at least tWo 
biomarkers is sometimes referred to as a “biomarker pro?le” 
or “biomarker ?ngerprint.” A combination of the biomarkers 
set forth in Tables 1, 3 and 4 can be detected. Similarly, one or 
more of the biomarkers set forth in Tables 1, 3 and 4 can be 
detected in combination With other knoWn ovarian cancer 
biomarkers, such as CAl25. Examples of knoWn ovarian 
cancer biomarkers useful in combination With the biomarkers 
of the present invention include, but are not limited to, those 
set forth in PCT Publications Nos. WO 03/057014 and WO 
2004/012588, both of Which are incorporated herein by ref 
erence for all purposes. 
The protocols described in the Examples beloW Were used 
to generate mass spectra from 65 patient samples, 30 of Which 
Were diagnosed With ovarian cancer and 35 of Which did not 
exhibit ovarian cancer. The peak masses and heights Were 
abstracted into a discovery data set. This data set Was used to 
train a learning algorithm employing classi?cation and 
regression tree analysis (CART) (Ciphergen Biomarker Pat 
terns SoftWareTM). lnparticular, CART chose many subsets of 
the peaks at random. For each subset, CART generated a best 
or near best decision tree to classify a sample as ovarian 
cancer (malignant), ovarian cancer LMP, benign ovarian dis 
ease or other malignant condition. Among the many decision 
trees generated by CART, several had excellent sensitivity 
and speci?city in distinguishing ovarian cancer (malignant, 
such as invasive epithelial ovarian cancer) from ovarian can 
cer of loW malignant potential versus benign ovarian disease. 
It is also noted that the speci?cs of the decision trees, in 
particular the cut-off values used in making branching deci 
sions, depends on the details of the assay used to generate the 
discovery data set. The data acquisition parameters of the 
assay that produced the data used in the present analysis is 
provided in the Example. In developing a classi?cation algo 
rithm from, for example, a neW sample set or a different assay 
protocol, the operator uses a protocol that detects these biom 
arkers and keys the learning algorithm to include them. 
Also, a diagnostic test for ovarian cancer status involving 
the measurement of any biomarker of this invention in com 
bination With any of the folloWing biomarkers for ovarian 
cancer identi?ed in Table 2 (including their modi?ed forms 
Where appropriate): 
TABLE 2 
Marker Comments (up- or down-regulated in cancer) 
CTAP3 
Transferrin 
Haptoglobin precursor protein fragment 
ApoAl 
Transthyretin and transthyretin delta N 10 
ITIH4 intemal fragments 
Up-regulated; 9293D 
IMAC-Cu 100 mM Na phosphate, pH 7.0 
Down-regulated; 79 kD, detected on IMAC 
ProteinChip array charged With nickel 
WO 03/057014 
Up-regulated; 9.2 kD detected on IMAC 
ProteinChip array charged With nickel 
WO 03/057014 
Down-regulated; predicted mass 28078.62D; 
detected on IMAC or H50 ProteinChip array. 
WO 2004/013609 
Down-regulated; predicted mass l376lD and 
12887 D, respectively; detected on Q10 
ProteinChip array. 
WO 2004/013609 
Up-regulated; among other fragments: 
MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF 
(SEQ ID NO: 1), a fragment spanning amino 
acids 660-689 of human Inter-alpha trypsin 
inhibitor, heavy chain H4, predicted mass: 
3273.72 D; detected on IMAC ProteinChip array 
WO 2004/013609 and WO 2005/098447 
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Marker Comments (up- or down-regulated in cancer) 
Beta 2-micro globulin 
ProteinChip array 
Up-regulated; detected at 11.7 KD on IMAC-Cu 
US Provisional Application No. 60/693,679, ?led 
Jun. 24, 2005 
Hepcidin and modi?ed forms 
precipitate with ITIH4 fragment. 
Hepcidin-25 (SEQ ID NO: 2): 
Up-regulated; detected by SELDI - co 
DTHFPICIFCCGCCHRSKCGMCCKT 
Hepcidin-24 (SEQ ID NO: 3): 
THFPICIFCCGCCHRSKCGMCCKT 
Hepcidin-22 (SEQ ID NO: 3): 
FPICIFCCGCCHRSKCGM CCKT 
Hepcidin-20 (SEQ ID NO: 4): 
ICIFCCGCCHRSKCGMCCKT 
Haptoglobin alpha Up-regulated. Detected at 11,600D-11,700D on 
an IMAC ProteinChip array charged with 
copper; 
WO 02/100242 
Up-regulated 
US. Pat. No. 6,846,642 
Up-regulated 
Pro statin 
Osteop ontin 
In urine - Glycosylated -- US 2005-0009120 A1 
In serum - US 2005-0214826 
Eosinophil-derived neurotoXin Up regulated in urine. Glycosylated Detected at 
17.4 KDa on a WCX2 ProteinChip array. 
US 2005-0009120 A1 
leptin Down-regulated; 
US 2005-0214826 
prolactin Up-regulated; 
US 2005-0214826 
IGF-II Down-regulated; 
US 2005-0214826 
Hemoglobin (alpha-hemoglobin, beta- Up-regulated; 
hemoglobin) WO 2006-019906 
CA 125 Up-regulated 
Other biomarkers with which the biomarkers of the present 
invention can be combined include, but are not limited to, 
CTAP3, CA125 II, CA15-3, CA19-9, CA72-4, CA 195, 
tumor associated trypsin inhibitor (TATI), CEA, placental 
alkaline phosphatase (PLAP), Sialyl TN, galactosyltrans 
ferase, macrophage colony stimulating factor (M-CSF, CSF 
1), lysophosphatidic acid (LPA), 110 kD component of the 
extracellular domain of the epidermal growth factor receptor 
(p110EGFR), tissue kallikreins, e.g., kallikrein 6 and kal 
likrein 10 (N ES-l), prostasin, HE4, creatine kinase B (CKB), 
LASA, HER-2/neu, urinary gonadotropin peptide, Dianon 
NB 70/ K, Tissue peptide antigen (TPA), SMRP, osteopontin, 
and haptoglobin, leptin, prolactin, insulin like growth factor I 
or II. 
Ovarian Cancer Status 
Determining ovarian cancer status typically involves clas 
sifying an individual into one of two or more groups (statuses) 
based on the results of the diagnostic test. The diagnostic tests 
described herein can be used to classify between a number of 
different states. 
Presence of Ovarian Cancer 
In one embodiment, this invention provides methods for 
determining the presence of ovarian cancer in a subject (sta 
tus: ovarian cancer versus ovarian cancer of low malignant 
potential or benign ovarian disease). The presence or absence 
of ovarian cancer is determined by measuring the relevant 
biomarker or biomarkers and then either submitting them to a 
classi?cation algorithm or comparing them with a reference 
amount and/or pattern of biomarkers that is associated with 
the particular risk level. 
Determining Risk of Developing Disease 
In one embodiment, this invention provides methods for 
determining the risk of developing disease in a subject. Biom 
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arker amounts or patterns are characteristic of various risk 
states, e.g., high, medium or low. The risk of developing a 
disease is determined by measuring the relevant biomarker or 
biomarkers and then either submitting them to a classi?cation 
algorithm or comparing them with a reference amount and/or 
pattern of biomarkers that is associated with the particular 
risk level. 
Determining Stage of Disease 
In one embodiment, this invention provides methods for 
determining the stage of disease in a subject. Each stage of the 
disease has a characteristic amount of a biomarker or relative 
amounts of a set of biomarkers (a pattern). The stage of a 
disease is determined by measuring the relevant biomarker or 
biomarkers and then either submitting them to a classi?cation 
algorithm or comparing them with a reference amount and/or 
pattern of biomarkers that is associated with the particular 
stage. For example, one can classify between early stage 
ovarian cancer and non-ovarian cancer or among stage I ova 
rian cancer, stage II ovarian cancer and stage III ovarian 
cancer. 
Determining Course (Progression/Remission) of Disease 
In one embodiment, this invention provides methods for 
determining the course of disease in a subject. Disease course 
refers to changes in disease status over time, including dis 
ease progression (worsening) and disease regression (im 
provement). Over time, the amounts or relative amounts (e.g., 
the pattern) of the biomarkers changes. Therefore, the trend of 
these markers, either increased or decreased over time toward 
diseased or non-diseased indicates the course of the disease. 
Accordingly, this method involves measuring one or more 
biomarkers in a subject at least two different time points, e.g., 
a ?rst time and a second time, and comparing the change in 
amounts, if any. The course of disease is determined based on 
these comparisons. 
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Similarly, changes in the rate of disease progression (or 
regression) may be monitored by measuring the amount of a 
biomarker, e. g., a peptide biomarkers of Table l, at different 
times and calculating the rate of change in biomarker levels. 
The ability to measure disease state or velocity of disease 
progression can be important for drug treatment studies 
Where the goal is to sloW doWn or arrest disease progression 
through therapy. 
Reporting the Status 
Additional embodiments of the invention relate to the com 
munication of assay results or diagnoses or both to techni 
cians, physicians or patients, for example. In certain embodi 
ments, computers Will be used to communicate assay results 
or diagnoses or both to interested parties, e.g., physicians and 
their patients. In some embodiments, the assays Will be per 
formed or the assay results analyZed in a country or jurisdic 
tion Which differs from the country or jurisdiction to Which 
the results or diagnoses are communicated. 
In a preferred embodiment of the invention, a diagnosis 
based on the differential presence in a test subject of any of the 
peptide biomarkers of Tables 1, 3 or 4 is communicated to the 
subject as soon as possible after the diagnosis is obtained. The 
diagnosis may be communicated to the subject by the sub 
ject’s treating physician. Alternatively, the diagnosis may be 
sent to a test subject by email or communicated to the subject 
by phone. A computer may be used to communicate the 
diagnosis by email or phone. In certain embodiments, the 
message containing results of a diagnostic test may be gen 
erated and delivered automatically to the subject using a 
combination of computer hardWare and softWare Which Will 
be familiar to artisans skilled in telecommunications. One 
example of a healthcare-oriented communications system is 
described in US. Pat. No. 6,283,761; hoWever, the present 
invention is not limited to methods Which utiliZe this particu 
lar communications system. In certain embodiments of the 
methods of the invention, all or some of the method steps, 
including the assaying of samples, diagnosing of diseases, 
and communicating of assay results or diagnoses, may be 
carried out in diverse (e.g., foreign) jurisdictions. 
Subject Management 
In certain embodiments of the methods of qualifying ova 
rian cancer status, the methods further comprise managing 
subject treatment based on the status. Such management 
includes the actions of the physician or clinician subsequent 
to determining ovarian cancer status. For example, if a phy 
sician makes a diagnosis of ovarian cancer, then a certain 
regime of treatment, such as prescription or administration of 
an anti-chemotherapeutic agent might folloW. Alternatively, a 
diagnosis of ovarian cancer LMP or benign ovarian disease 
might be folloWed With further testing to determine a speci?c 
disease that might the patient might be suffering from. Also, 
if the diagnostic test gives an inconclusive result on ovarian 
cancer status, further tests may be called for. 
Additional embodiments of the invention relate to the com 
munication of assay results or diagnoses or both to techni 
cians, physicians or patients, for example. In certain embodi 
ments, computers Will be used to communicate assay results 
or diagnoses or both to interested parties, e.g., physicians and 
their patients. In some embodiments, the assays Will be per 
formed or the assay results analyZed in a country or jurisdic 
tion Which differs from the country or jurisdiction to Which 
the results or diagnoses are communicated. 
In a preferred embodiment of the invention, a diagnosis 
based on the presence or absence in a test subject of any the 
biomarkers of Table l is communicated to the subject as soon 
as possible after the diagnosis is obtained. The diagnosis may 
be communicated to the subject by the subject’s treating 
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physician. Alternatively, the diagnosis may be sent to a test 
subject by email or communicated to the subject by phone. A 
computer may be used to communicate the diagnosis by 
email or phone. In certain embodiments, the message con 
taining results of a diagnostic test may be generated and 
delivered automatically to the subject using a combination of 
computer hardWare and softWare Which Will be familiar to 
artisans skilled in telecommunications. One example of a 
healthcare-oriented communications system is described in 
US. Pat. No. 6,283,761; hoWever, the present invention is not 
limited to methods Which utiliZe this particular communica 
tions system. In certain embodiments of the methods of the 
invention, all or some of the method steps, including the 
assaying of samples, diagnosing of diseases, and communi 
cating of assay results or diagnoses, may be carried out in 
diverse (e.g., foreign) jurisdictions. 
VI. Determining Therapeutic Ef?cacy of 
Pharmaceutical Drug 
In another embodiment, this invention provides methods 
for determining the therapeutic ef?cacy of a pharmaceutical 
drug. These methods are useful in performing clinical trials of 
the drug, as Well as monitoring the progress of a patient on the 
drug. Therapy or clinical trials involve administering the drug 
in a particular regimen. The regimen may involve a single 
dose of the drug or multiple doses of the drug over time. The 
doctor or clinical researcher monitors the effect of the drug on 
the patient or subject over the course of administration. If the 
drug has a pharmacological impact on the condition, the 
amounts or relative amounts (e. g., the pattern or pro?le) of the 
biomarkers of this invention changes toWard a non-disease 
pro?le. For example, biomarkers ApoCI and hemoglobin are 
increased With disease, While biomarker M32600 is 
decreased in disease. Therefore, one can folloW the course of 
the amounts of these biomarkers in the subject during the 
course of treatment. Accordingly, this method involves mea 
suring one or more biomarkers in a subject receiving drug 
therapy, and correlating the amounts of the biomarkers With 
the disease status of the subject. One embodiment of this 
method involves determining the levels of the biomarkers at at 
least tWo different time points during a course of drug therapy, 
e.g., a ?rst time and a second time, and comparing the change 
in amounts of the biomarkers, if any. For example, the biom 
arkers can be measured before and after drug administration 
or at tWo different time points during drug administration. 
The effect of therapy is determined based on these compari 
sons. If a treatment is effective, then the biomarkers Will trend 
toWard normal, While if treatment is ineffective, the biomar 
kers Will trend toWard disease indications. If a treatment is 
effective, then the biomarkers Will trend toWard normal, While 
if treatment is ineffective, the biomarkers Will trend toWard 
disease indications. 
VII. Generation of Classi?cation Algorithms for 
Qualifying Ovarian Cancer Status 
In some embodiments, data derived from the spectra (e. g., 
mass spectra or time-of-?ight spectra) that are generated 
using samples such as “knoWn samples” can then be used to 
“train” a classi?cation model. A “knoWn sample” is a sample 
that has been pre-classi?ed. The data that are derived from the 
spectra and are used to form the classi?cation model can be 
referred to as a “training data set.” Once trained, the classi? 
cation model can recogniZe patterns in data derived from 
spectra generated using unknoWn samples. The classi?cation 
model can then be used to classify the unknoWn samples into 
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classes. This canbe useful, for example, in predicting Whether 
or not a particular biological sample is associated With a 
certain biological condition (e.g., diseased versus non-dis 
eased). 
The training data set that is used to form the classi?cation 
model may comprise raW data or pre-processed data. In some 
embodiments, raW data can be obtained directly from time 
of-?ight spectra or mass spectra, and then may be optionally 
“pre-processed” as described above. 
Classi?cation models can be formed using any suitable 
statistical classi?cation (or “leaming”) method that attempts 
to segregate bodies of data into classes based on objective 
parameters present in the data. Classi?cation methods may be 
either supervised or unsupervised. Examples of supervised 
and unsupervised classi?cation processes are described in 
Jain, “Statistical Pattern Recognition: A Review,” IEEE 
Transactions on Pattern Analysis and Machine Intelligence, 
Vol. 22, No. 1, January 2000, the teachings of Which are 
incorporated by reference. 
In supervised classi?cation, training data containing 
examples of knoWn categories are presented to a learning 
mechanism, Which learns one or more sets of relationships 
that de?ne each of the knoWn classes. NeW data may then be 
applied to the learning mechanism, Which then classi?es the 
neW data using the learned relationships. Examples of super 
vised classi?cation processes include linear regression pro 
cesses (e.g., multiple linear regression (MLR), partial least 
squares (PLS) regression and principal components regres 
sion (PCR)), binary decision trees (e. g., recursive partitioning 
processes such as CARTiclassi?cation and regression 
trees), arti?cial neural netWorks such as back propagation 
netWorks, discriminant analyses (e.g., Bayesian classi?er or 
Fischer analysis), logistic classi?ers, and support vector clas 
si?ers (support vector machines). 
A preferred supervised classi?cation method is a recursive 
partitioning process. Recursive partitioning processes use 
recursive partitioning trees to classify spectra derived from 
unknoWn samples. Further details about recursive partition 
ing processes are provided in US. Patent Application No. 
2002/0138208 A1 to Paulse et al., “Method for AnalyZing 
Mass Spectra.” 
In other embodiments, the classi?cation models that are 
created can be formed using unsupervised learning methods. 
Unsupervised classi?cation attempts to learn classi?cations 
based on similarities in the training data set, Without pre 
classifying the spectra from Which the training data set Was 
derived. Unsupervised learning methods include cluster 
analyses. A cluster analysis attempts to divide the data into 
“clusters” or groups that ideally should have members that are 
very similar to each other, and very dissimilar to members of 
other clusters. Similarity is then measured using some dis 
tance metric, Which measures the distance betWeen data 
items, and clusters together data items that are closer to each 
other. Clustering techniques include the MacQueen’s 
K-means algorithm and the Kohonen’ s Self-Organizing Map 
algorithm. 
Learning algorithms asserted for use in classifying biologi 
cal information are described, for example, in PCT Interna 
tional Publication No. WO 01/31580 (Barnhill et al., “Meth 
ods and Devices for Identifying Patterns in Biological 
Systems and Methods of Use Thereof”), US. Patent Appli 
cation No. 2002 0193950 A1 (Gavin et al., “Method or ana 
lyZing mass spectra”), US. Patent Application No. 2003 
0004402 A1 (Hitt et al., “Process for Discriminating BetWeen 
Biological States Based on Hidden Patterns from Biological 
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Data”), and US. Patent Application No. 2003 0055615 A1 
(Zhang et al., “Systems and Methods for Processing Biologi 
cal Expression Data”). 
The classi?cation models can be formed on and used on 
any suitable digital computer. Suitable digital computers 
include micro, mini, or large computers using any standard or 
specialiZed operating system, such as a Unix, WindoWsTM or 
LinuxTM based operating system. The digital computer that is 
used may be physically separate from the mass spectrometer 
that is used to create the spectra of interest, or it may be 
coupled to the mass spectrometer. 
The training data set and the classi?cation models accord 
ing to embodiments of the invention can be embodied by 
computer code that is executed or used by a digital computer. 
The computer code can be stored on any suitable computer 
readable media including optical or magnetic disks, sticks, 
tapes, etc., and can be Written in any suitable computer pro 
gramming language including C, C++, visual basic, etc. 
The learning algorithms described above are useful both 
for developing classi?cation algorithms for the biomarkers 
already discovered, or for ?nding neW biomarkers for ovarian 
cancer. The classi?cation algorithms, in turn, form the base 
for diagnostic tests by providing diagnostic values (e.g., cut 
off points) for biomarkers used singly or in combination. 
VIII. Use of Biomarkers for Imaging 
Non-invasive medical imaging techniques such as Positron 
Emisson Tomography (PET) or single photon emission com 
puteriZed tomography (SPECT) imaging are particularly use 
ful for the detection of cancer, coronary artery disease and 
brain disease. PET and SPECT imaging shoWs the chemical 
functioning of organs and tissues, While other imaging tech 
niquesisuch as X-ray, CT and MRIiShOW structure. The 
use of PET and SPECT imaging has become increasingly 
useful for qualifying and monitoring the development of 
brain diseases such as AlZheimer’s disease. In some 
instances, the use of PET or SPECT imaging alloWs AlZhe 
imer’s disease to be detected several years earlier than the 
onset of symptoms. See, e. g.,Vassaux and Groot-Wassink, “In 
Vivo Noninvasive Imaging for Gene Therapy,” J. Biomedi 
cine and Biotechnology, 2: 92-101 (2003). 
Different strategies are being used to develop compounds 
suitable for in vivo imaging of amyloid deposits in human 
brains. Monoclonal antibodies against A-beta and peptide 
fragments have had limited uptake by the brain When tested in 
patients With AD. The small molecular approach for amyloid 
imaging has so far been most successful, as described by, e. g., 
Nordberg A, Lancet Neurol., 3(9):519-27 (2004); Kung MP 
et al, Brain Res., 1025(1-2):98-105 (2004); HerholZ K et al., 
Mol Imaging Biol., 6(4):239-69 (2004); Neuropsychol Rev., 
ZakZanis K K et al., 13(1): 1 -1 8 (2003); HerholZ K, Ann Nucl 
Med., 17(2):79-89 (2003). 
The peptide biomarkers disclosed herein, or fragments 
thereof, can be used in the context of PET and SPECT imag 
ing applications. After modi?cation With appropriate tracer 
residues for PET or SPECT applications, peptide biomarkers 
Which interact With amyloid plaque proteins can be used to 
image the deposition of amyloid plaques in AlZheimer’s 
patients. 
Antisense technology may be used to detect expression of 
transcripts Whose translation is correlated With the biomark 
ers identi?ed herein. For example, the use of antisense pep 
tide nucleic acid (PNA) labeled With an appropriate radionu 
clide, such as 11 1In, and conjugated to a brain drug-targeting 
system to enable transport across biologic membrane barri 
ers, has been demonstrated to alloW imaging of endogenous 
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gene expression in brain cancer. See Suzuki et al., Journal of 
Nuclear Medicine, 10: 1766-1775 (2004). Suzuki et al. utilize 
a delivery system comprising monoclonal antibodies that tar 
get transferring receptors at the blood-brain barrier and facili 
tate transport of the PNA across that barrier. 
IX. Compositions of Matter 
In another aspect, this invention provides compositions of 
matter based on the biomarkers of this invention. 
In one embodiment, this invention provides biomarkers of 
this invention in puri?ed form. Puri?ed biomarkers have util 
ity as antigens to raise antibodies. Puri?ed biomarkers also 
have utility as standards in assay procedures. As used herein, 
a “puri?ed biomarker” is a biomarker that has been isolated 
from other proteins and peptides, and/ or other material from 
the biological sample in Which the biomarker is found. Biom 
arkers may be puri?ed using any method knoWn in the art, 
including, but not limited to, mechanical separation (e.g., 
centrifugation), ammonium sulphate precipitation, dialysis 
(including size-exclusion dialysis), size-exclusion chroma 
tography, a?inity chromatography, anion-exchange chroma 
to graphy, cation-exchange chromatography, and methal-che 
late chromatography. Such methods may be performed at any 
appropriate scale, for example, in a chromatography column, 
or on a biochip. 
In another embodiment, this invention provides a biospe 
ci?c capture reagent, optionally in puri?ed form, that speci? 
cally binds a biomarker of this invention. In one embodiment, 
the biospeci?c capture reagent is an antibody. Such compo 
sitions are useful for detecting the biomarker in a detection 
assay, e.g., for diagnostics. 
In another embodiment, this invention provides an article 
comprising a biospeci?c capture reagent that binds a biom 
arker of this invention, Wherein the reagent is bound to a solid 
phase. For example, this invention contemplates a device 
comprising bead, chip, membrane, monolith or microtiter 
plate derivatized With the biospeci?c capture reagent. Such 
articles are useful in biomarker detection assays. 
In another aspect this invention provides a composition 
comprising a biospeci?c capture reagent, such as an antibody, 
bound to a biomarker of this invention, the composition 
optionally being in puri?ed form. Such compositions are 
useful for purifying the biomarker or in assays for detecting 
the biomarker. 
In another embodiment, this invention provides an article 
comprising a solid substrate to Which is attached an adsor 
bent, e. g., a chromatographic adsorbent or a biospeci?c cap 
ture reagent, to Which is further bound a biomarker of this 
invention. In one embodiment, the article is a biochip or a 
probe for mass spectrometry, e.g., a SELDI probe. Such 
articles are useful for purifying the biomarker or detecting the 
biomarker. 
X. Kits for Detection of Biomarkers for Ovarian 
Cancer 
In another aspect, the present invention provides kits for 
qualifying ovarian cancer status, Which kits are used to detect 
biomarkers according to the invention. In one embodiment, 
the kit comprises a solid support, such as a chip, a microtiter 
plate or a bead or resin having a capture reagent attached 
thereon, Wherein the capture reagent binds a biomarker of the 
invention. Thus, for example, the kits of the present invention 
can comprise mass spectrometry probes for SELDI, such as 
ProteinChip® arrays. In the case of biospeci?c capture 
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reagents, the kit can comprise a solid support With a reactive 
surface, and a container comprising the biospeci?c capture 
reagent. 
The kit can also comprise a Washing solution or instruc 
tions for making a Washing solution, in Which the combina 
tion of the capture reagent and the Washing solution alloWs 
capture of the biomarker or biomarkers on the solid support 
for subsequent detection by, e.g., mass spectrometry. The kit 
may include more than type of adsorbent, each present on a 
different solid support. 
In a further embodiment, such a kit can comprise instruc 
tions for suitable operational parameters in the form of a label 
or separate insert. For example, the instructions may inform a 
consumer about hoW to collect the sample, hoW to Wash the 
probe or the particular biomarkers to be detected. 
In yet another embodiment, the kit can comprise one or 
more containers With biomarker samples, to be used as stan 
dard(s) for calibration. 
XI. Use of Biomarkers for Ovarian Cancer in 
Screening Assays and Methods of Treating Ovarian 
Cancer 
The methods of the present invention have other applica 
tions as Well. For example, the biomarkers can be used to 
screen for compounds that modulate the expression of the 
biomarkers in vitro or in vivo, Which compounds in turn may 
be useful in treating or preventing ovarian cancer in patients. 
In another example, the biomarkers can be used to monitor the 
response to treatments for ovarian cancer. In yet another 
example, the biomarkers can be used in heredity studies to 
determine if the subject is at risk for developing ovarian 
cancer. 
Thus, for example, the kits of this invention could include 
a solid substrate having a hydrophobic function, such as a 
protein biochip (e.g., a Ciphergen H50 ProteinChip array, 
e.g., ProteinChip array) and a sodium acetate buffer for Wash 
ing the substrate, as Well as instructions providing a protocol 
to measure the biomarkers of this invention on the chip and to 
use these measurements to diagnose ovarian cancer. 
Compounds suitable for therapeutic testing may be 
screened initially by identifying compounds Which interact 
With one or more biomarkers listed in Tables 1, 3 and 4. By 
Way of example, screening might include recombinantly 
expressing a biomarker listed in Tables 1, 3 or 4, purifying the 
biomarker, and af?xing the biomarker to a substrate. Test 
compounds Would then be contacted With the substrate, typi 
cally in aqueous conditions, and interactions betWeen the test 
compound and the biomarker are measured, for example, by 
measuring elution rates as a function of salt concentration. 
Certain proteins may recognize and cleave one or more biom 
arkers of Tables 1, 3 and 4, in Which case the proteins may be 
detected by monitoring the digestion of one or more biomar 
kers in a standard assay, e.g., by gel electrophoresis of the 
proteins. 
In a related embodiment, the ability of a test compound to 
inhibit the activity of one or more of the biomarkers of Tables 
1, 3 and 4 may be measured. One of skill in the art Will 
recognize that the techniques used to measure the activity of 
a particular biomarker Will vary depending on the function 
and properties of the biomarker. For example, an enzymatic 
activity of a biomarker may be assayed provided that an 
appropriate substrate is available and provided that the con 
centration of the substrate or the appearance of the reaction 
product is readily measurable. The ability of potentially 
therapeutic test compounds to inhibit or enhance the activity 
of a given biomarker may be determined by measuring the 
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rates of catalysis in the presence or absence of the test com 
pounds. The ability of a test compound to interfere With a 
non-enZymatic (e. g., structural) function or activity of one of 
the biomarkers of Tables 1, 3 and 4 may also be measured. For 
example, the self-assembly of a multi-protein complex Which 
includes one of the biomarkers of Tables 1, 3 and 4 may be 
monitored by spectroscopy in the presence or absence of a test 
compound. Alternatively, if the biomarker is a non-enZymatic 
enhancer of transcription, test compounds Which interfere 
With the ability of the biomarker to enhance transcription may 
be identi?ed by measuring the levels of biomarker-dependent 
transcription in vivo or in vitro in the presence and absence of 
the test compound. 
Test compounds capable of modulating the activity of any 
of the biomarkers of Tables 1, 3 and 4 may be administered to 
patients Who are suffering from or are at risk of developing 
ovarian cancer or other cancer. For example, the administra 
tion of a test compound Which increases the activity of a 
particular biomarker may decrease the risk of ovarian cancer 
in a patient if the activity of the particular biomarker in vivo 
prevents the accumulation of proteins for ovarian cancer. 
Conversely, the administration of a test compound Which 
decreases the activity of a particular biomarker may decrease 
the risk of ovarian cancer in a patient if the increased activity 
of the biomarker is responsible, at least in part, for the onset 
of ovarian cancer. 
In an additional aspect, the invention provides a method for 
identifying compounds useful for the treatment of disorders 
such as ovarian cancer Which are associated With increased 
levels of modi?ed forms of Calgranulin C. For example, in 
one embodiment, cell extracts or expression libraries may be 
screened for compounds Which catalyze the cleavage of full 
length Calgranulin C (M10430) to truncated forms of Cal 
granulin C (M10210). In one embodiment of such a screening 
assay, cleavage of Calgranulin C may be detected by attach 
ing a ?uorophore to Calgranulin C Which remains quenched 
When Calgranulin C is uncleaved, but Which ?uoresces When 
the protein is cleaved. Alternatively, a version of full-length 
Calgranulin C modi?ed so as to render the amide bond 
betWeen amino acids x and y uncleavable may be used to 
selectively bind or “trap” the cellular protesase Which cleaves 
full-length Calgranulin C at that site in vivo. Methods for 
screening and identifying proteases and their targets are Well 
documented in the scienti?c literature, e.g., in LopeZ-Ottin et 
al. (Nature Reviews, 3:509-519 (2002)). 
In yet another embodiment, the invention provides a 
method for treating or reducing the progression or likelihood 
of a disease, e. g., ovarian cancer, Which is associated With the 
increased levels of truncated Calgranulin C. For example, 
after one or more proteins have been identi?ed Which cleave 
full-length Calgranulin C, combinatorial libraries may be 
screened for compounds Which inhibit the cleavage activity 
of the identi?ed proteins. Methods of screening chemical 
libraries for such compounds are Well-knoWn in art. See, e.g., 
LopeZ-Otin et al. (2002). Alternatively, inhibitory com 
pounds may be intelligently designed based on the structure 
of Calgranulin C. 
At the clinical level, screening a test compound includes 
obtaining samples from test subjects before and after the 
subjects have been exposed to a test compound. The levels in 
the samples of one or more of the biomarkers listed in Tables 
1, 3 and 4 may be measured and analyZed to determine 
Whether the levels of the biomarkers change after exposure to 
a test compound. The samples may be analyZed by mass 
spectrometry, as described herein, or the samples may be 
analyZed by any appropriate means knoWn to one of skill in 
the art. For example, the levels of one or more of the biom 
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arkers listed in Tables 1, 3 and 4 may be measured directly by 
Western blot using radio- or ?uorescently-labeled antibodies 
Which speci?cally bind to the biomarkers. Alternatively, 
changes in the levels of mRNA encoding the one or more 
biomarkers may be measured and correlated With the admin 
istration of a given test compound to a subject. In a further 
embodiment, the changes in the level of expression of one or 
more of the biomarkers may be measured using in vitro meth 
ods and materials. For example, human tissue cultured cells 
Which express, or are capable of expressing, one or more of 
the biomarkers of Tables 1, 3 and 4 may be contacted With test 
compounds. Subjects Who have been treated With test com 
pounds Will be routinely examined for any physiological 
effects Which may result from the treatment. In particular, the 
test compounds Will be evaluated for their ability to decrease 
disease likelihood in a subject. Alternatively, if the test com 
pounds are administered to subjects Who have previously 
been diagnosed With ovarian cancer, test compounds Will be 
screened for their ability to sloW or stop the progression of the 
disease. 
XII. Examples 
Example 1 
Discovery of Biomarkers for Ovarian Cancer 
Samples: 
Ovarian cyst ?uid samples Were acquired from the Univer 
sity of Kentucky. The samples had been collected from 
patients intra-operatively and stored at —80° C. Sample dis 
tribution Was as follows: invasive epithelial ovarian cancer 
(OvCa), 12; loW malignant potential (borderline), 13; other 
malignancies, 6; and benign, 39. 
Samples: Serum Pro?ling: 
Ovarian cyst pro?ling Was performed using both direct 
chip binding procedures as Well as anion exchange fraction 
ation folloWed by chip binding procedures. Randomized tem 
plates containing the samples to be pro?led Were generated 
using the Ciphergen Express softWare program. Samples 
Were thaWed on ice, added to a 96 Well-plate (folloWing the 
template for arrangement), and centrifuged for 20 minutes at 
4000 rpm. Aliquots of the cyst ?uid Were then put into fresh 
96 Well-plates and stored at —80° C. until use. Serum samples 
Were pro?led on IMAC-Cu++ on Oct. 6, 2004 and on Q10 on 
Oct. 14, 2004 (see, protocol beloW) on triplicate ProteinChip 
Arrays. All replicates Were prepared on the same day and 
Were read on a PCS4000. Arrays Were processed With sample 
using a Biomek 2000 or Tecan Aquarius robot. 
Direct Chip Binding Protocol: 
1. 5 ul sample Was denatured With 7.5 ul U9 buffer. 
2. Shake at 40 C. for 20 minutes. 
3. Added 112.5 pl 50 mM tris, pH9 buffer to make ?nal 
volume as 125 pl. 
4. 5 ul of this denature sample Was applied to all four chip 
types. 
Chip Binding: 
IMAC30: IMAC30 ProteinChip arrays Were coupled With 
copper. The binding and Washing buffer Was 50 mM Tris 
pH 8.0/500 mM NaCl. 
CM10: The binding and Washing buffer Was 100 mM 
NaAcetate pH 4.0. 
H50: The binding and Washing buffer Was 10% acetonitrile 
buffer. 
Q10: The binding and Washing buffer Was 50 mM tris 
buffer at pH8.0. 
Binding time: 60 minutes at room temperature. 
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Matrix Was Sinapinic Acid. 
1. Anion Exchange Fractionation Protocol: 
Buffer List: 
U9 (9 M urea, 2% CHAPS, 50 mM Tris-HCl pH9). 
. U1 (1 M urea, 0.22% CHAPS, 50 mM Tris-HCl pH9). 
. 50 mM Tris-HCl With 0.1% OGP pH9 (Wash buffer 1). 
. 50 mM Hepes With 0.1% OGP pH7 (Wash buffer 2). 
. 100 mM NaAcetate With 0.1% OGP pH5 (Wash buffer 
3). 
6. 100 mM NaAcetate With 0.1% OGP pH4 (Wash buffer 
4). 
7. 50 mM NaCitrate With 0.1% OGP pH3 (Wash buffer 5). 
8. 33.3% isopropanol/l 6.7% acetonitrile/0. 1% tri?uorace 
tic acid (Wash buffer 6). 
Note: Do not aliquot Wash buffer 6 into the buffer tray until 
Wash buffer 5 is being applied to the resin. This ensures 
that evaporation of the volatile organic solvents Will not 
be an issue. 
Material List: 
Filter plate. 
6 v-Well 96 Well dishes, labeled Fl-F6. 
A. Wash Resin 
Prepare resin by Washing Hyper Q DF resin 3 times With 5 
bed volumes 50 mM Tris-HCl pH9. Then store in 50 mM 
Tris-HCl pH9 in a 50% suspension. 
B. Denature Serum Protein 
ThaW frozen serum and spin 20000 g for 10' at 4°. 
Aliquot 20 pl serum to each Well of the 96-Well plate. 
Add 30 pl U9 to each sample. 
Vortex 20' at 4°. 
C. Equilibrate Resin 
Add 180 pl (240 pl for rat serum) Hyper Q DF to each Well 
in ?lter plate. 
Filter buffer. 
Add 200 pl Ul to each Well. 
Filter buffer. 
Add 200 pl Ul to each Well. 
Filter buffer. 
Add 200 pl Ul to each Well. 
Filter buffer. 
D. Bind Serum With Resin 
Pipet 50 pl of sample from each Well to corresponding Well 
in ?lter plate. 
Add 50 pl of U1 to each Well of sample plate. 
Mix 5 times. 
Pipet 50 pl from each Well of sample plate to corresponding 
Well in ?lter plate. 
[This step is included because there is a dead volume When 
pipeting With the robot; When the robot pipets to collect 
the sample the ?rst time, it Will not collect all the mate 
rial. The addition of 50 pl U1 and mixing alloWs the 
residual material to be obtained and added to the ?rst 50 
ill-1 
Vortex 30' at 40 
E. Collect Fractions 
Place v-Well 96 Well plate Fl under ?lter plate. 
Collect ?oW-through in plate Fl. 
Add 100 pl of Wash buffer 1 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Collect pH 9 eluant in plate Fl. 
Fraction 1 contains the How through and the pH 9 eluant. 
Add 100 pl of Wash buffer 2 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Place v-Well 96 Well plate F2 under ?lter plate. 
Collect fraction 2 in plate F2. 
Add 100 pl of Wash buffer 2 to each Well of ?lter plate. 
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Vortex 10' at Room Temperature (RT). 
Collect remainder of fraction 2 in plate F2. 
Fraction 2 contains the pH 7 eluant. 
Add 100 pl of Wash buffer 3 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Place v-Well 96 Well plate F3 under ?lter plate. 
Collect fraction 3 in plate F3. 
Add 100 pl of Wash buffer 3 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Collect remainder of fraction 3 in plate F3. 
Fraction 3 contains the pH 5 eluant. 
Add 100 pl of Wash buffer 4 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Place v-Well 96 Well plate F4 under ?lter plate. 
Collect fraction 4 in plate F4. 
Add 100 pl of Wash buffer 4 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Collect remainder of fraction 4 in plate F4. 
Fraction 4 contains the pH 4 eluant. 
Add 100 pl of Wash buffer 5 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Place v-Well 96 Well plate F5 under ?lter plate. 
Collect fraction 5 in plate F5. 
Add 100 pl of Wash buffer 5 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Collect remainder of fraction 5 in plate F5. 
Fraction 5 contains the pH 3 eluant. 
Add 100 pl of Wash buffer 6 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Place v-Well 96 Well plate F6 under ?lter plate. 
Collect fraction 6 in plate F6. 
Add 100 pl of Wash buffer 6 to each Well of ?lter plate. 
Vortex 10' at Room Temperature (RT). 
Collect remainder of fraction 6 in plate F6. 
Fraction 6 contains the organic solvent eluant. 
FreeZe until proceeding With chip binding protocol. 
Chip Binding Protocol 
Buffer List: 
lMAC30 Chip: 
1. 100 mM Sodium Phosphate+0.5M NaCl pH 7.0. 
2. 100 mM CuSO4. 
3. 100 mM NaAcetate pH 4.0. 
CMl0 Chip: 
1. 100 mM Sodium Acetate pH 4.0 
Material List: 
Bioprocessors. 
lMAC30 chips. 
CMl0 chips. 
Place chips into bioprocessor. 
A. Load LMAC Chips With Copper 
Load 50 pl of CuSO4 onto each spot on the EVlAC3 chip. 
Centrifuge the bioprocessor at 700 rpm for 1 minutes. 
Vortex 5' at Room Temperature (RT). 
Remove CuSO4 after Vortex. 
Water rinse. 
B. NeutraliZe lMAC Chips 
Load 50 pl of NaAcetate pH 4.0 onto each spot on the 
lMAC3 chip. 
Vortex 5' at Room Temperature (RT). 
Remove NaAcetate after Vortex. 
Water rinse. 
C. Equilibrate Chips 
Add 150 pl of appropriate chip binding buffer into each 
Well. 
Centrifuge the bioprocessor at 700 rpm for 1 minutes for 
CM10. 
Vortex 5' at Room Temperature (RT). 
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Remove buffer. 
Add 150 pl of appropriate buffer into each Well. 
Vortex 5' at Room Temperature (RT). 
Remove buffer after vortex. 
D. Bind Fractions to Chips 
Add 90 ul of corresponding buffer into each Well. 
Add 10 ul of Q column fraction. 
Centrifuge the bioprocessor at 700 rpm for 1 minutes for 
CM10. 
Vortex 60' at Room Temperature (RT). 
Remove sample and buffer. 
E. Wash Chips 
Add 150 pl of corresponding buffer into each Well. 
Vortex 5' at Room Temperature (RT). 
Remove buffer after vortexing. 
Add 150 p. 1 of corresponding buffer into each Well. 
Vortex 5' at Room Temperature (RT). 
Remove buffer after vortexing. 
Add 150 pl of corresponding buffer into each Well. 
Vortex 5' at Room Temperature (RT). 
Remove buffer after vortexing. 
Water rinse 2 times. 
F. Add Matrix 
Remove bioprocessor top and gasket. 
Remove the Water from spots With vacuum. 
AlloW the chips to dry 10 minutes. 
DraW a circle around each spot using a pap pen. 
For SPA: 
Add 400 pl of 50% ACN, 0.5% TFA to SPA tube. 
Vortex 5 minutes at RT. 
Add 1.0 ul to each spot. 
Air dry 10 minutes. 
Add 1.0 ul to each spot. 
Air dry. 
Data Analysis: 
Data Were acquired using CiphergenExpress. Mass cali 
bration Was performed using external calibrants, intensity 
normalization Was based on total ion current using an external 
normalization factor, and baseline subtraction Was per 
formed. Peak detection Was performed in CiphergenExpress 
using the criteria that a peak must have a signal/noise ratio of 
3:1 and be present in 20% of the spectra. Statistical analysis 
Was performed in CiphergenExpress using the Mann-Whit 
ney test (for tWo groups, e.g., benign versus ovarian cancer) or 
Kruskal-Wallis test (for multiple group comparison, e.g., 
benign ovarian disease versus ovarian cancer versus ovarian 
cancer With loW malignant potential (LMP) versus other 
malignancies (such as malignancies other than invasive epi 
thelial ovarian cancer, including metastatic cancer (e.g., gas 
tric cancer frequently metastasiZes to the ovary), mesothe 
lioma, a stromal ovarian cancer, etc. 
Results/ Conclusions: 
A four-Way comparison Was performed using the Kruskal 
Wallis test. The four groups Were benign ovarian disease, 
invasive epithelial ovarian cancer, borderline ovarian cancer 
(also called ovarian cancer With loW malignant potential), and 
other malignancies (Which include stromal ovarian tumor, 
metastatic disease, and uterine cancer). 
The biomarkers for ovarian cancer in ovarian cyst ?uid 
identi?ed using the above methods are set forth in Table 1. 
Most notably, it has been determined that most peaks of 
signi?cance are similarly up- or doWn-regulated based on the 
characteristics of malignancy (or not) of the disease. Benign 
disease and ovarian cancer of loW malignant potential (also 
called borderline disease) tend to have the same distribution 
of peak intensity, While invasive ovarian cancer and other 
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malignant diseases tend to have the same distribution of peak 
intensity. These biomarkers of the present invention can be 
used alone, or in conjunction With, other proteins previously 
identi?ed to be important biomarkers for ovarian cancer. 
Example 2 
Marker Puri?cation and ID 
Biomarkers Were puri?ed using combinations of chro 
matographic techniques employing a range of Biosepra sor 
bents typically folloWed by SDS-PAGE. The puri?cation 
schemes Were monitored using a ProteinChip Reader to track 
biomarkers of interest. For proteins smaller than 30 kDa, 
intact bands of interest Were extracted from gels and reana 
lyZed using the ProteinChip Reader to con?rm their exact 
masses matched With the original biomarker. The gel-ex 
tracted proteins Were in-solution digested With trypsin and 
proteins larger than 30 kDa Were in-gel digested. Tryptic 
digests Were analyZed by peptide mapping using the Protein 
Chip Reader and by tandem MS using a Q-STAR (Applied 
Biosystems) instrument ?tted With a PC1-1000 ProteinChip 
Interface. Biomarkers smaller than 4 kDa Were enriched by 
combinations of chromatographic techniques and identi?ed 
directly by tandem MS Without SDS-PAGE puri?cation and/ 
or trypsin digestion. In some instances (e.g., LysoZyme C) the 
biomarkers Were identi?ed using antibodies. 
The techniques described in the preceding paragraph 
alloWed the identi?cation of the biomarkers of Table 1 
Example 3 
Discovery of Biomarkers 
Methods 
Protein expression pro?ling Was performed on ovarian cyst 
?uids from seventy-four patients With ovarian tumors (16 
malignant, 13 of loW malignant potential, 45 benign) using 
the ProteinChip Biomarker System® (Ciphergen Biosys 
tems), a platform for surface-enhanced laser desorption/ion 
iZation time-or-?ight mass spectrometry. Ovarian cyst ?uid 
Was analyZed unfractionated, and also folloWing anion 
exchange fractionation. Aliquots of each fraction Were ana 
lyZed in duplicate on NP20, lMAC30, CM10, H50, and Q10 
ProteinChip arrays. Ciphergen Express® softWare Was used 
to identify m/ Z peaks and to compare peak intensity betWeen 
diagnostic groups. Statistically signi?cant differences in peak 
intensity betWeen diagnostic groups Were determined by 
Kruskal-Wallis test and ROC curve analysis. 
Results 
Over one hundred protein peaks from ovarian cyst ?uid 
differed signi?cantly in peak intensity betWeen benign, 
malignant, and ovarian tumors of loW malignant potential 
(see, Tables 2 and 3, beloW). Of these cyst ?uid proteins, the 
folloWing have been identi?ed by MS/MS or MS/MS With 
immunoassay validation: Apolipoprotein C l (m/Z:6520, 
p:0.0003), ApolipoproteinA ll (m/Z:8690, p:0.00006), and 
Apolipoprotein Cll (m/ZI8918, p:0.0002); Calgranulin A 
(m/Z:10840, p:0.00001) and Calgranulin C (m/Z:10430, 
p:0.00004); Transthyretin (doubly charged) (m/Z:6880, 
p:0.00005); and Calcyclin (m/Z:10210, p:00002). 
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TABLE 3 
US 8,465,929 B2 
SELDI-TOF MS analyses of anion exchange fractionated cyst fluids from individual 
patients adsorbed to CM10 ProteinChip arrays and read at high laser intensity 
have identi?ed thirty-?ve biornarkers that differ betWeen patients With benign 
and loW malignant potential turnors versus malignant epithelial ovarian tumors. 
M/Z M/Z Std. Fraction(s) P—value(s) ROC(s) 
2414 3.49 1, 2, 5 0.0085, 0.0085, 0.01263 0.231, 0.269, 0.25 
2429 6.46 1 0.00407 0.212 
3286 5.03 5 0.01091 0.731 
3353 3.76 5 0.00850 0.731 
3446 5.08 2, 6 0.01681, 0.00407 0.718, 0.782 
3517 5.06 6 0.00365 0.782 
3562 5.86 6 0.01263 0.731 
4227 7.39 5 0.00988 0.250 
4302 13.26 5 0.00034 0.854 
4558 5.85 5 0.00003 0.878 
4733 6.57 4, 5 0.01604, 0.01459 0.25, 0.269 
4958 9.22 5 0.00430 0.250 
6395 9.67 1, 5 0.0013, 0.00479 0.814, 0.737 
6443 22.16 1, 4 0.02893, 0.00027 0.66, 0.827 
6507 8.8 6 0.00035 0.814 
6604 6.02 1 0.00075 0.782 
7136 14.81 1 0.00505 0.744 
7535 2.57 4 0.00003 0.878 
7910 4.71 4 0.00003 0.897 
8100 21.18 1 0.01391 0.731 
8331 19.94 1 0.01845 0.692 
8554 14.59 1 0.00767 0.737 
10836 9.21 2, 4 0.02535, 0.03741 0.699, 0.667 
11733 4.89 3 0.00592 0.288 
12693 7.59 1 0.01038 0.718 
13130 18.92 1 0.04417 0.673 
13273 8.49 1 0.0043 0.756 
13291 18.99 2 0.03437 0.699 
13891 13.07 4 0.00003 0.891 
15082 27.66 3 0.00186 0.75 
15127 20.16 5 0.00208 0.788 
15212 31.3 6 0.00155 0.788 
15335 21.31 4 0.00003 0.878 
15878 23.46 3, 4, 5, 6 0.00345, 0.00002, 0.0001, 0.00004 0.801, 0.897, 0.854, 0.865 
15987 15.01 3 4 0.00175, 0.00002 0.807, 0.878 
Kruskal-Wallis P-value(s) and AUC values from ROC analyses are shown. 
AUC values < 0.5 indicate that “peak intensity” Was decreased in the ovarian cancer cases. 
TABLE 4 
SELDI-TOF MS analyses of anion exchange fractionated cyst fluids from individual 
patients adsorbed to CM10 ProteinChip arrays and read at lOW laser intensity have 
identi?ed twenty-eight biornarkers that differ betWeen patients With benign and 
lOW malignant potential tumors versus malignant epithelial ovarian tumors. 
M/Z M/Z Std. Fraction(s) P—value(s) ROC(s) 
3368 2.9 6 5.00E-05 0.865 
3377 3.21 1, 5 0.0231, 0.01761 0.699, 0.699 
3439 3.22 1, 5, 6 0.01681, 0.01932, 0.00196 0.718, 0.698, 0.788 
3487 2.52 5, 6 0.00175, 0.00261 0.769, 0.788 
4349 4.11 5 0.03901 0.679 
4626 2.27 5 0.00002 0.878 
6431 5.35 1, 4, 5, 6 0.00005, 0.00008, 0.00155, 0.00196 0.891, 0.846, 0.769, 0.56 
6461 7.72 1 0.00185 0.794 
6496 5.51 1 0.00261 0.775 
6643 5.91 1 0.00004 0.858 
6830 9.37 1 0.01681 0.698 
6926 5.7 6 0.00001 0.923 
7566 2.76 4 0.00002 0.878 
7654 13.53 1 0.00505 0.737 
7936 4.89 3, 4 0.00075, 0.00002 0.8, 0.897 
8134 5.69 1 0.00479 0.75 
8577 9.55 1 0.00479 0.737 
9117 3.52 2 0.0085 0.288 
10847 13.11 1, 2, 3, 4 0.00006, 0.02769, 0.03586, 0.02023 0.884, 0.66, 0.66, 0.724 
12711 8 1 0.01391 0.72 
13279 17.93 1 0.00233 0.77 
13887 14.8 4 0.00004 0.891 
15140 20.99 3, 4, 5, 6 0.00327, 0.000004, 0.0043, 0.00011 0.75, 0.897, 0.75, 0.846 
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